KCTD16: An Auxiliary Subunit of GABA_B Receptors

Introduction

KCTD16 (potassium channel tetramerization domain-containing protein 16; UniProt Q68DU8) is a BTB/POZ domain-containing protein that functions as an auxiliary subunit of metabotropic GABA_B receptors in the mammalian nervous system. The protein was initially identified through its sequence homology to the tetramerization domain of voltage-gated potassium channels, though KCTD16 itself does not form ion channels[schwenk-2010-gabab-kctd-discovery-abstract]. Rather, KCTD16 serves as a critical modulator of inhibitory neurotransmission by determining the pharmacology and kinetics of GABA_B receptor-mediated G-protein signaling[schwenk-2010-gabab-kctd-discovery-abstract]. The protein is highly expressed in brain regions including the cerebral cortex, hippocampus, and amygdala, where it plays essential roles in shaping the temporal dynamics of GABAergic inhibition.

The discovery of KCTD proteins as GABA_B receptor auxiliary subunits in 2010 fundamentally transformed understanding of this receptor system[schwenk-2010-gabab-kctd-discovery-abstract]. Prior to this work, GABA_B receptors were believed to function as simple heterodimers of GABA_B1 and GABA_B2 subunits. Proteomic analysis revealed that native receptors are actually high-molecular-weight complexes containing the principal subunits plus auxiliary KCTD proteins, explaining functional diversity that could not be reproduced with cloned receptors alone[schwenk-2010-gabab-kctd-discovery-abstract]. KCTD16, along with the related proteins KCTD8, KCTD12, and KCTD12b, defines molecularly and functionally distinct GABA_B receptor subtypes throughout the brain.

Protein Structure and Domain Architecture

KCTD16 belongs to clade F of the KCTD protein family and contains three major structural domains: a conserved N-terminal T1/BTB domain, an H1 homology domain, and a C-terminal H2 domain[liu-2013-kctd-family-review-abstract][seddik-2012-h1h2-domains-abstract]. The T1/BTB domain mediates oligomerization and receptor binding, while the H1 and H2 domains regulate desensitization kinetics. Among the GABA_B receptor-associated KCTDs, only KCTD8 and KCTD16 possess both H1 and H2 domains; KCTD12 and KCTD12b lack the H2 domain entirely[seddik-2012-h1h2-domains-abstract].

Crystallographic studies have determined the high-resolution structure of human KCTD16's T1 domain at 2.3 Ångström resolution, revealing that it forms an open pentameric ring structure with an inner diameter of approximately 25 Ångströms[zuo-2019-kctd16-structure-abstract]. This open pentamer architecture is stabilized by extensive salt bridges at subunit interfaces, particularly involving charged residues along an alpha-3 helix. The pentameric structure of KCTD16 contrasts with the tetrameric organization of the homologous T1 domains in voltage-gated potassium channels, though both share the same fold[liu-2013-kctd-family-review-abstract]. Notably, unlike many other BTB domain-containing proteins, KCTD16 does not interact with the Cullin3 ubiquitin ligase, indicating that its function is specialized for receptor modulation rather than protein degradation[zuo-2019-kctd16-structure-abstract].

The binding interface between KCTD16 and the GABA_B2 receptor has been mapped in atomic detail. A single GABA_B2 C-terminal peptide binds to the interior of the open pentamer formed by five KCTD16 subunits, establishing a 1:5 stoichiometry[zuo-2019-kctd16-structure-abstract]. The phenylalanine residue at position 80 (F80) from each of the first four KCTD16 subunits creates hydrophobic grooves that accommodate the receptor peptide through hydrogen bonding, aromatic stacking, and hydrophobic contacts[zuo-2019-kctd16-structure-abstract]. Mutagenesis studies confirmed the functional importance of this interface: the F80A mutation in KCTD16 and corresponding Y903S/L904D mutations in GABA_B2 significantly reduced both coimmunoprecipitation efficiency and the ability of KCTD16 to modulate GIRK channel activation kinetics[zuo-2019-kctd16-structure-abstract].

Molecular Function: Modulation of GABA_B Receptor Signaling

The primary molecular function of KCTD16 is to modulate GABA_B receptor-mediated G-protein signaling and the subsequent activation of effector ion channels[schwenk-2010-gabab-kctd-discovery-abstract]. GABA_B receptors are metabotropic receptors for gamma-aminobutyric acid (GABA), the principal inhibitory neurotransmitter in the brain. Upon agonist binding, these receptors activate heterotrimeric G-proteins (primarily G_i/o), leading to release of Gβγ subunits that directly gate G-protein-coupled inwardly rectifying potassium (GIRK) channels to produce slow inhibitory postsynaptic currents (IPSCs)[turecek-2014-gprotein-uncoupling-abstract].

KCTD16 increases agonist potency at GABA_B receptors and accelerates the onset of GIRK channel activation[schwenk-2010-gabab-kctd-discovery-abstract]. The mechanism involves the KCTD16 T1 domain recognizing the GABA_B2 C-terminus to tether the H1 domain near the receptor's distal tail, positioning it for interaction with released Gβγ subunits[zheng-2019-desensitization-nature-abstract]. Structural and biochemical studies have demonstrated that the H1 domain engages in a symmetric interaction with five copies of Gβγ, with the G-protein subunits also interacting directly with one another[zheng-2019-desensitization-nature-abstract]. This cooperative binding allows KCTD proteins to efficiently regulate the availability of Gβγ for effector channel activation.

Beyond its role in G-protein modulation, KCTD16 performs critical scaffolding functions by anchoring multiple effector channels to GABA_B receptors. Recent research has demonstrated that KCTD16 associates GABA_B receptors with HCN channels containing HCN2 and HCN3 subunits, forming a multiprotein signaling complex[perezgarci-2025-hcn-anxiety-abstract]. This interaction has profound functional consequences: during inhibitory postsynaptic potentials (IPSPs), the hyperpolarization produced by GABA_B receptor-activated potassium currents simultaneously activates the tethered HCN channels, generating an inward hyperpolarization-activated current (I_h) that counteracts and limits the duration of the IPSP[perezgarci-2025-hcn-anxiety-abstract]. This negative feedback mechanism, mediated specifically by KCTD16, provides rapid desensitization of inhibitory responses through a mechanism distinct from the Gβγ sequestration employed by KCTD12[perezgarci-2025-hcn-anxiety-abstract].

In addition to HCN channels, KCTD16 acts as a scaffold protein that links GABA_B receptors to voltage-gated N-type calcium channels (Cav2.2)[trovo-2024-synaptotagmin11-abstract]. A 2024 study revealed that synaptotagmin-11 (Syt11), a vesicular protein, binds simultaneously to both KCTD16 and Cav2.2 channels, facilitating the assembly of GABA_B receptor/Cav2.2 signaling complexes in post-Golgi transport vesicles[trovo-2024-synaptotagmin11-abstract]. This mechanism ensures that pre-assembled receptor-channel signaling complexes are transported together to their functional sites at synapses. Syt11 also stabilizes GABA_B receptors and Cav2.2 channels at the neuronal plasma membrane by inhibiting constitutive internalization[trovo-2024-synaptotagmin11-abstract]. Neurons lacking Syt11 exhibit reduced presynaptic Cav2.2 channels and GABA_B receptors, diminished neurotransmitter release, and weakened GABA_B receptor-mediated inhibition of release[trovo-2024-synaptotagmin11-abstract]. These findings reveal that KCTD16 serves as a central hub for organizing presynaptic signaling machinery, coordinating the spatial coupling of GABA_B receptors with their primary effector channels for synaptic modulation.

A distinguishing feature of KCTD16, compared to KCTD12 and KCTD12b, is that it generates primarily non-desensitizing receptor responses[seddik-2012-h1h2-domains-abstract]. While KCTD12 promotes rapid desensitization of GABA_B receptor-induced GIRK currents by sequestering Gβγ subunits away from effector channels, KCTD16 produces sustained, slowly deactivating responses[turecek-2014-gprotein-uncoupling-abstract][fritzius-2017-heterooligomers-abstract]. This functional difference is attributable to the presence of the H2 domain in KCTD16, which inhibits the desensitization-promoting activity of the H1 domain through a steric mechanism[seddik-2012-h1h2-domains-abstract].

The molecular basis for the opposing effects of H1 and H2 domains has been characterized through domain-swapping experiments[seddik-2012-h1h2-domains-abstract]. The H1 domains of KCTD12 and KCTD12b contain a critical T/NFLEQ sequence motif that mediates desensitization; this motif is not present in the H1 domains of KCTD8 or KCTD16[seddik-2012-h1h2-domains-abstract]. When the H2 domain of KCTD16 is attached to the C-terminus of KCTD12, the resulting chimera loses desensitizing properties, demonstrating the dominant inhibitory effect of H2[seddik-2012-h1h2-domains-abstract]. However, removal of the H2 domain from KCTD16 does not convert it into a desensitizing protein, indicating that the KCTD16 H1 domain itself lacks the capacity to promote desensitization[seddik-2012-h1h2-domains-abstract]. Evolutionary analysis suggests that KCTD12 and KCTD12b acquired desensitizing properties by disposing of their inhibitory H2 domains while selecting for the T/NFLEQ motif in their H1 domains[seddik-2012-h1h2-domains-abstract].

Hetero-oligomerization and Functional Diversity

While KCTD proteins were initially assumed to function as homo-oligomers, subsequent research demonstrated that they can also assemble into hetero-oligomers in all possible dual combinations[fritzius-2017-heterooligomers-abstract]. This finding significantly expands the molecular and functional repertoire of native GABA_B receptors. Coimmunoprecipitation experiments using adult mouse brain tissue revealed that approximately two-thirds of KCTD16 in the hippocampus associates with KCTD12, forming KCTD12/KCTD16 hetero-oligomers[fritzius-2017-heterooligomers-abstract]. These hetero-oligomers form at least tetramers and directly interact with both the receptor and associated G-proteins through their self-associating T1 and H1 domains[fritzius-2017-heterooligomers-abstract].

KCTD12/KCTD16 hetero-oligomers confer unique kinetic properties to GABA_B receptor-induced potassium currents that differ from either homo-oligomer[fritzius-2017-heterooligomers-abstract]. During prolonged receptor activation (approximately one minute), KCTD12/KCTD16 hetero-oligomers produce moderately desensitizing, fast-deactivating currents. In contrast, KCTD12 homo-oligomers generate strongly desensitizing, fast-deactivating currents, while KCTD16 homo-oligomers produce non-desensitizing, slowly deactivating currents[fritzius-2017-heterooligomers-abstract]. During brief activation periods (approximately two seconds), hetero-oligomers produce non-desensitizing, slowly deactivating responses similar to KCTD16 homo-oligomers[fritzius-2017-heterooligomers-abstract].

The physiological significance of hetero-oligomer formation was demonstrated through electrophysiological recordings in hippocampal neurons from knockout mice[fritzius-2017-heterooligomers-abstract]. These experiments indicated that KCTD12/KCTD16 hetero-oligomers increase the duration of slow IPSCs in pyramidal cells, providing a molecular mechanism for fine-tuning the temporal properties of GABAergic inhibition in hippocampal circuits[fritzius-2017-heterooligomers-abstract].

Subcellular Localization and Tissue Expression

KCTD16 exhibits a primarily cytoplasmic localization with enrichment in the central nervous system[vancoevorden-2019-encephalitis-abstract]. The protein associates with GABA_B receptors at the plasma membrane through its interaction with the GABA_B2 C-terminus; an F80A mutation abolishes this GABA_B-mediated membrane localization in cultured cells[zuo-2019-kctd16-structure-abstract]. Additional subcellular localization studies have detected KCTD16 at the centrosome and in vesicular structures, though the functional significance of these non-membrane locations remains to be determined.

Expression profiling data from the Human Protein Atlas indicates that KCTD16 is most highly expressed in the cerebral cortex (7.1 nTPM), with substantial expression also in the hippocampal formation (2.8 nTPM) and amygdala (2.2 nTPM). Outside the brain, enhanced expression is detected in the retina (1.8 nTPM) and pancreas (1.4 nTPM), while most other tissues show minimal expression. At the single-cell level, KCTD16 is most abundant in brain excitatory neurons (645.1 nCPM), brain inhibitory neurons (589.1 nCPM), oligodendrocyte progenitor cells (491.9 nCPM), and adrenal medulla cells (436.1 nCPM), consistent with its role in regulating inhibitory neurotransmission in neural circuits.

Biological Processes and Physiological Functions

KCTD16 functions within the broader context of GABA_B receptor-mediated inhibitory neurotransmission, which controls neuronal excitability through regulation of potassium and calcium channels[schwenk-2010-gabab-kctd-discovery-abstract]. The protein influences the duration and kinetics of slow IPSCs, thereby shaping the temporal dynamics of synaptic inhibition in neural circuits[fritzius-2017-heterooligomers-abstract]. Through its non-desensitizing properties, KCTD16-containing GABA_B receptors are suited for sustained inhibitory responses that may be important during prolonged or repeated GABAergic input.

Behavioral studies in KCTD16 knockout mice have revealed specific roles in fear memory processing[cathomas-2017-knockout-behavior-abstract]. While initial fear conditioning is normal in these animals, KCTD16 knockout mice display reduced extinction of auditory fear memory and enhanced contextual fear retention compared to wild-type littermates[cathomas-2017-knockout-behavior-abstract]. Circadian activity patterns remain unaffected. These findings suggest that KCTD16 influences fear-related behaviors that may serve as endophenotypes for hyper-reactivity to aversive stimuli, with potential relevance to anxiety disorders and post-traumatic stress disorder[cathomas-2017-knockout-behavior-abstract].

A particularly important physiological role for KCTD16 has been identified in dopamine neurons of the ventral tegmental area (VTA)[perezgarci-2025-hcn-anxiety-abstract]. Aversive stimuli inhibit these DA_VTA neurons, and this inhibition is prolonged by GABA_B receptor-activated potassium currents. The KCTD16-mediated tethering of HCN channels to GABA_B receptors provides a negative feedback mechanism that limits the duration of this inhibition[perezgarci-2025-hcn-anxiety-abstract]. When KCTD16 is genetically ablated, either globally or specifically in DA_VTA neurons using CRISPR/Cas9, the result is prolonged optogenetic inhibition of DA_VTA neuron firing and increased anxiety-like behavior in response to stress[perezgarci-2025-hcn-anxiety-abstract]. This phenotype can be replicated by intra-VTA infusion of HCN antagonists in wild-type mice, confirming that the HCN channel anchoring function of KCTD16 is mechanistically responsible for the behavioral effect[perezgarci-2025-hcn-anxiety-abstract]. These findings establish that the GABA_B receptor/HCN channel complex organized by KCTD16 serves as a protective mechanism against anxiety development by restricting IPSP duration in the VTA reward circuitry.

The formation of KCTD12/KCTD16 hetero-oligomers in the hippocampus has implications for learning and memory circuits. By prolonging the duration of slow IPSCs in pyramidal cells, these hetero-oligomers may influence the temporal integration of inhibitory inputs and the balance between excitation and inhibition that underlies hippocampal function[fritzius-2017-heterooligomers-abstract]. GWAS studies have linked KCTD proteins more broadly to various neuropsychiatric conditions including autism spectrum disorder, bipolar disorder, major depression, and substance use disorders, though specific associations for KCTD16 require further investigation.

Notably, KCTD16 exhibits brain region-specific expression and function. While abundant in the cortex, hippocampus, and VTA, KCTD16 mRNA levels are very low in the medial habenula according to the Allen Brain Atlas[ren-2022-habenula-axonal-abstract]. In habenula cholinergic neurons, the related proteins KCTD8 and KCTD12, rather than KCTD16, play the dominant role in facilitating axonal GABA_B receptor expression and presynaptic modulation[ren-2022-habenula-axonal-abstract]. This regional specialization highlights that different KCTD isoforms have evolved to serve distinct functions in specific neural circuits.

Clinical Relevance and Disease Associations

The most well-characterized disease association for KCTD16 involves autoimmune encephalitis. Anti-GABA_B receptor encephalitis is an autoimmune condition mediated by antibodies targeting the GABA_B receptor complex, typically presenting with severe seizures, cognitive and behavioral changes, and limbic system involvement[vancoevorden-2019-encephalitis-abstract]. Research has identified KCTD16 as a novel autoantibody target in this condition, with KCTD16 antibodies detected in 72% (23/32) of patients with anti-GABA_B receptor encephalitis[vancoevorden-2019-encephalitis-abstract].

Importantly, the presence of KCTD16 autoantibodies marks a paraneoplastic origin and correlates strongly with underlying malignancy[vancoevorden-2019-encephalitis-abstract]. Among adequately screened patients, 95% of those with KCTD16 antibodies had tumors (primarily small cell lung carcinoma) compared to only 33% of anti-GABA_B receptor encephalitis patients without KCTD16 antibodies (P=0.001)[vancoevorden-2019-encephalitis-abstract]. This association suggests that tumor cells may express GABA_B receptor components including KCTD16, triggering antibody production through molecular mimicry. The addition of KCTD16 to diagnostic cell-based assays improves sensitivity for detecting GABA_B receptor antibodies without compromising specificity[vancoevorden-2019-encephalitis-abstract].

Clinical features of anti-GABA_B receptor encephalitis include cognitive or behavioral changes (97%), prominent seizures (90%), and status epilepticus requiring intensive care unit admission (42%)[vancoevorden-2019-encephalitis-abstract]. A notable finding was that 4/32 patients presented with rapidly progressive dementia as a clinical feature. Most patients (22/26) showed improvement with immunotherapy or chemotherapy[vancoevorden-2019-encephalitis-abstract]. These findings establish KCTD16 as a clinically relevant biomarker and therapeutic target in autoimmune neurology.

Cancer profiling has identified KCTD16 as a prognostic marker in kidney renal papillary cell carcinoma, though the mechanistic basis for this association remains unexplored. The highest expression in cancer cell lines is observed in neuroblastoma, consistent with the protein's neuronal expression pattern.

Therapeutic Development

The structural characterization of KCTD16 and its interaction with GABA_B receptors has enabled initial drug discovery efforts. In a pioneering study, researchers developed a peptide-based inhibitor targeting the KCTD-GABA_B receptor protein-protein interaction[sereikaite-2019-drug-discovery-abstract]. Using μSPOT technology to map the receptor's binding region for KCTD proteins, they designed a highly potent peptide inhibitor capable of efficiently isolating endogenous KCTD proteins from mouse brain lysates[sereikaite-2019-drug-discovery-abstract]. Crystallographic and SEC-MALS analysis revealed that this inhibitor induces KCTD16 to adopt a distinct hexameric structure, different from its native pentameric form[sereikaite-2019-drug-discovery-abstract]. This work establishes proof-of-concept for targeting receptor-associated protein complexes as an alternative to direct receptor modulation, representing a fundamentally novel approach for developing therapeutics for GABA_B receptor-associated neuropsychiatric disorders[sereikaite-2019-drug-discovery-abstract].

The rationale for targeting the KCTD-GABA_B interaction is compelling because it offers the potential for more selective modulation than direct receptor agonists or antagonists. Since different KCTD isoforms confer distinct functional properties and are expressed in specific brain regions, targeting individual KCTD-receptor interactions could allow circuit-specific manipulation of GABA_B signaling. The identification of KCTD16's role in VTA dopamine neuron inhibition and anxiety[perezgarci-2025-hcn-anxiety-abstract] suggests that modulators of KCTD16 function could have therapeutic potential for anxiety disorders, while the association with autoimmune encephalitis[vancoevorden-2019-encephalitis-abstract] points to possible applications in autoimmune neurology.

Evolutionary and Comparative Biology

The KCTD protein family comprises 26 members in humans with varying degrees of functional characterization[liu-2013-kctd-family-review-abstract]. KCTD16 is classified in clade F alongside KCTD8, sharing the distinctive feature of possessing both H1 and H2 domains[liu-2013-kctd-family-review-abstract]. Evolutionary analysis suggests that the functional diversification of GABA_B receptor-associated KCTD proteins occurred through domain loss and sequence evolution[seddik-2012-h1h2-domains-abstract]. The desensitizing KCTD12 and KCTD12b variants evolved by disposing of their inhibitory H2 domains while acquiring the T/NFLEQ motif necessary for Gβγ sequestration[seddik-2012-h1h2-domains-abstract]. This evolutionary elaboration of KCTD-mediated GABA_B receptor regulation appears to be a vertebrate innovation, as invertebrate organisms lack these specialized auxiliary subunits[seddik-2012-h1h2-domains-abstract].

The conserved binding interface between KCTD16 and GABA_B2, with critical residues F80 and the corresponding receptor residues Y903/L904 maintained across species, suggests strong selective pressure to preserve this interaction[zuo-2019-kctd16-structure-abstract]. The structural studies reveal that this conserved interaction mechanism applies broadly across the GABA_B receptor-associated KCTD proteins (8, 12, 12b, and 16), indicating an ancestral binding mode that has been maintained through evolution while the functional properties encoded by other domains have diversified[zuo-2019-kctd16-structure-abstract].

Open Questions

Several important questions remain regarding KCTD16 biology and function. First, while the structure of KCTD16's T1 domain bound to GABA_B2 has been determined, the structural basis of H2 domain-mediated inhibition of desensitization remains unclear. How does the H2 domain sterically interfere with the desensitization-promoting activity of H1, and what conformational changes occur upon receptor activation? Second, the precise stoichiometry and composition of native KCTD complexes in different brain regions and cell types requires further investigation. What factors determine whether homo-oligomers or hetero-oligomers form at a given synapse, and how is this regulated during development and plasticity?

Third, the structural basis of KCTD16's scaffolding function for HCN channels requires elucidation. Which domains of KCTD16 mediate interaction with HCN2/HCN3 subunits, and is this interaction direct or mediated through intermediate proteins? Understanding this would enable more precise targeting of this interaction therapeutically. Fourth, the relationship between KCTD16 function and fear memory processing warrants deeper mechanistic investigation. While VTA dopamine neurons have been implicated, which specific hippocampal and amygdala circuits depend on KCTD16 for normal fear extinction?

Fifth, the mechanism by which KCTD16 autoantibodies contribute to encephalitis pathogenesis needs elucidation. Do these antibodies directly impair GABA_B receptor function, or do they promote receptor internalization or complement-mediated cell damage? The intracellular location of KCTD16 raises questions about how extracellular antibodies access their target. Sixth, the discovery of peptide inhibitors that induce KCTD16 hexamerization opens questions about whether this alternative oligomeric state has any physiological relevance or could be exploited therapeutically.

Finally, given the distinct expression patterns of KCTD isoforms across brain regions, a comprehensive map of KCTD16 distribution at cellular resolution would inform understanding of where KCTD16-specific functions are most relevant. The low expression in habenula but high expression in VTA suggests that KCTD16 may play specialized roles in reward and motivation circuits that deserve further investigation.

References

1. [schwenk-2010-gabab-kctd-discovery-abstract] Schwenk J, Metz M, Zolles G, et al. Native GABA(B) receptors are heteromultimers with a family of auxiliary subunits. Nature. 2010;465(7295):231-235. doi:10.1038/nature08964. PMID: 20400944. URL: https://www.nature.com/articles/nature08964

2. [zuo-2019-kctd16-structure-abstract] Zuo H, Glaaser IW, Zhao Y, et al. Structural basis for auxiliary subunit KCTD16 regulation of the GABAB receptor. Proc Natl Acad Sci U S A. 2019;116(17):8370-8379. doi:10.1073/pnas.1903024116. PMID: 30971491; PMCID: PMC6486783. URL: https://pmc.ncbi.nlm.nih.gov/articles/PMC6486783/

3. [zheng-2019-desensitization-nature-abstract] Zheng S, Abreu N, Levitz J, Kruse AC. Structural basis for KCTD-mediated rapid desensitization of GABAB signalling. Nature. 2019;567(7746):127-131. doi:10.1038/s41586-019-0990-0. PMID: 30814734; PMCID: PMC6405316. URL: https://www.nature.com/articles/s41586-019-0990-0

4. [seddik-2012-h1h2-domains-abstract] Seddik R, Jungblut SP, Silander OK, et al. Opposite effects of KCTD subunit domains on GABA(B) receptor-mediated desensitization. J Biol Chem. 2012;287(47):39869-39877. doi:10.1074/jbc.M112.412767. PMID: 23035119; PMCID: PMC3501043. URL: https://pmc.ncbi.nlm.nih.gov/articles/PMC3501043/

5. [turecek-2014-gprotein-uncoupling-abstract] Turecek R, Schwenk J, Fritzius T, et al. Auxiliary GABAB receptor subunits uncouple G protein βγ subunits from effector channels to induce desensitization. Neuron. 2014;82(5):1032-1044. doi:10.1016/j.neuron.2014.04.015. PMID: 24836506. URL: https://www.sciencedirect.com/science/article/pii/S0896627314003055

6. [fritzius-2017-heterooligomers-abstract] Fritzius T, Turecek R, Seddik R, et al. KCTD Hetero-oligomers Confer Unique Kinetic Properties on Hippocampal GABAB Receptor-Induced K+ Currents. J Neurosci. 2017;37(5):1162-1175. doi:10.1523/JNEUROSCI.2181-16.2016. PMID: 28003345; PMCID: PMC6596860. URL: https://www.jneurosci.org/content/37/5/1162

7. [cathomas-2017-knockout-behavior-abstract] Cathomas F, Sigrist H, Schmid L, Seifritz E, Gassmann M, Bettler B, Pryce CR. Behavioural endophenotypes in mice lacking the auxiliary GABAB receptor subunit KCTD16. Behav Brain Res. 2017;317:393-400. doi:10.1016/j.bbr.2016.10.006. PMID: 27717812. URL: https://www.sciencedirect.com/science/article/abs/pii/S0166432816307653

8. [vancoevorden-2019-encephalitis-abstract] van Coevorden-Hameete MH, de Bruijn MAAM, de Graaff E, et al. The expanded clinical spectrum of anti-GABABR encephalitis and added value of KCTD16 autoantibodies. Brain. 2019;142(6):1631-1643. doi:10.1093/brain/awz094. PMID: 31009048; PMCID: PMC6536844. URL: https://academic.oup.com/brain/article/142/6/1631/5476117

9. [liu-2013-kctd-family-review-abstract] Liu Z, Xiang Y, Sun G. The KCTD family of proteins: structure, function, disease relevance. Cell Biosci. 2013;3(1):45. doi:10.1186/2045-3701-3-45. PMID: 24268103; PMCID: PMC3882106. URL: https://cellandbioscience.biomedcentral.com/articles/10.1186/2045-3701-3-45

10. [perezgarci-2025-hcn-anxiety-abstract] Pérez-Garci E, Pysanenko K, Rizzi G, et al. Binding of HCN channels to GABAB receptors in dopamine neurons of the VTA limits synaptic inhibition and prevents the development of anxiety. Neurobiol Dis. 2025;206:106831. doi:10.1016/j.nbd.2025.106831. PMID: 39914775. URL: https://www.sciencedirect.com/science/article/pii/S0969996125000476

11. [sereikaite-2019-drug-discovery-abstract] Sereikaite V, Fritzius T, Kasaragod VB, et al. Targeting the γ-Aminobutyric Acid Type B (GABAB) Receptor Complex: Development of Inhibitors Targeting the K+ Channel Tetramerization Domain (KCTD) Containing Proteins/GABAB Receptor Protein-Protein Interaction. J Med Chem. 2019;62(19):8819-8830. doi:10.1021/acs.jmedchem.9b01087. PMID: 31509708. URL: https://pubs.acs.org/doi/abs/10.1021/acs.jmedchem.9b01087

12. [ren-2022-habenula-axonal-abstract] Ren Y, Liu Y, Zheng S, Luo M. KCTD8 and KCTD12 Facilitate Axonal Expression of GABAB Receptors in Habenula Cholinergic Neurons. J Neurosci. 2022;42(9):1648-1665. doi:10.1523/JNEUROSCI.1676-21.2021. PMID: 35017224; PMCID: PMC8896537. URL: https://www.jneurosci.org/content/42/9/1648

13. [trovo-2024-synaptotagmin11-abstract] Trovò L, Kouvaros S, Schwenk J, et al. Synaptotagmin-11 facilitates assembly of a presynaptic signaling complex in post-Golgi cargo vesicles. EMBO Rep. 2024;25(6):2610-2634. doi:10.1038/s44319-024-00147-0. PMID: 38698221; PMCID: PMC11169412. URL: https://pmc.ncbi.nlm.nih.gov/articles/PMC11169412/

Citations

1. cathomas-2017-knockout-behavior-abstract.md
2. fritzius-2017-heterooligomers-abstract.md
3. fritzius-2017-heterooligomers-summary.md
4. liu-2013-kctd-family-review-abstract.md
5. perezgarci-2025-hcn-anxiety-abstract.md
6. ren-2022-habenula-axonal-abstract.md
7. schwenk-2010-gabab-kctd-discovery-abstract.md
8. schwenk-2010-gabab-kctd-discovery-summary.md
9. seddik-2012-h1h2-domains-abstract.md
10. seddik-2012-h1h2-domains-summary.md
11. sereikaite-2019-drug-discovery-abstract.md
12. trovo-2024-synaptotagmin11-abstract.md
13. turecek-2014-gprotein-uncoupling-abstract.md
14. vancoevorden-2019-encephalitis-abstract.md
15. zheng-2019-desensitization-nature-abstract.md
16. zuo-2019-kctd16-structure-abstract.md
17. zuo-2019-kctd16-structure-summary.md

The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.

You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.

We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.

We are interested in where in or outside the cell the gene product carries out its function.

We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.

Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.

Plan
- Verified identity and domains; collected and evaluated recent and foundational sources; synthesized mechanistic function, interactions, signaling context, localization, and clinical relevance; compiled quantitative/statistical data and built an evidence table artifact; composed the final report with citations.

Comprehensive research report: human KCTD16 (UniProt Q68DU8)

1) Key concepts and definitions with current understanding
- Identity, family, domains, organism verification: KCTD16 (gene symbol KCTD16, also known as KIAA1317) is a human potassium channel tetramerization domain-containing protein that belongs to the KCTD family. It contains an N‑terminal BTB/POZ (T1) oligomerization domain and C‑terminal homology regions (H1, and in some members H2). Structural work using human protein fragments confirms that the BTB/T1 forms an open pentamer and binds the distal cytoplasmic tail of the GABAB2 subunit, verifying both the gene symbol and human organism context specified (PDB 6OCP; PNAS 2019). The BTB/POZ and T1‑type BTB domain annotations align with the literature (BTB/POZ/T1 oligomerization module; H1 module for Gβγ engagement in paralogs) (https://doi.org/10.1073/pnas.1903024116; https://doi.org/10.1038/s41586-019-0990-0) (zuo2019structuralbasisfor pages 1-1, zheng2019structuralbasisfor pages 1-2, zuo2019structuralbasisfor pages 7-7, zheng2019structuralbasisfor pages 2-4).
- Functional class: KCTD16 is an auxiliary subunit of metabotropic GABAB receptors (GBRs). Native GBR complexes comprise principal subunits GABAB1 and GABAB2 plus auxiliary KCTDs (notably KCTD8, KCTD12/12b, KCTD16). KCTD16 modulates GBR signaling kinetics and amplitude, particularly in coupling to G protein-gated inwardly rectifying K+ channels (GIRK) (https://doi.org/10.1073/pnas.1903024116; https://doi.org/10.1038/s41586-019-0990-0) (zuo2019structuralbasisfor pages 1-1, zheng2019structuralbasisfor pages 1-2).

2) Mechanism, interactions, pathways, and localization
- Direct molecular interfaces and stoichiometry: The KCTD16 BTB/T1 domain forms an open pentamer that wraps around one copy of the GABAB2 C-terminal peptide, establishing a 1:5 GB2 peptide:KCTD16 stoichiometry. Key interfacial residues include KCTD16 Q34, F80, P101, E102 and GABAB2 I898, Y903, L904; mutating these residues disrupts both biochemical association and functional modulation of GBR→GIRK currents (https://doi.org/10.1073/pnas.1903024116) (zuo2019structuralbasisfor pages 1-3, zuo2019structuralbasisfor pages 7-7, zuo2019structuralbasisfor pages 9-10).
- H1–Gβγ engagement and desensitization paradigm: KCTD family H1 domains can oligomerize to bind multiple Gβγ heterodimers cooperatively in a 5:5 complex, enabling rapid desensitization of GBR→GIRK signaling by stripping Gβγ from GIRK after initial activation. Quantitative measures for KCTD12 show H1–Gβγ KD ~185 nM and cooperative 5:5 assembly; analogous architecture and receptor tethering is proposed to underlie KCTD effects broadly, including KCTD16 (https://doi.org/10.1038/s41586-019-0990-0) (zheng2019structuralbasisfor pages 2-4, zheng2019structuralbasisfor pages 12-16).
- Kinetic specialization among KCTDs: KCTD12/12b enforce rapid desensitization of GABAB‑evoked GIRK currents by Gβγ sequestration, whereas KCTD8 and KCTD16 generally confer primarily non‑desensitizing/sustained responses; KCTD8/16 possess additional C‑terminal features (including H2) that oppose desensitization (https://doi.org/10.1073/pnas.1903024116) (zuo2019structuralbasisfor pages 1-3, zuo2019structuralbasisfor pages 1-1).
- Pathway context: KCTD16 operates within the canonical GBR pathway (GABAB→Gi/o→Gβγ→GIRK; and presynaptically Gβγ→VGCC inhibition), shaping postsynaptic inhibitory K+ currents and presynaptic release probability. Allosteric and G protein readouts show KCTD-dependent modulation of G protein conformations and cAMP pathway efficacy across KCTD paralogs; KCTD8/12/16 redundantly sustain the efficacy of inhibitory GPCR signals to cAMP in neurons (https://doi.org/10.1016/j.neuropharm.2014.08.020; https://doi.org/10.1073/pnas.2119237119) (rajalu2015pharmacologicalcharacterizationof pages 5-7, muntean2022membersofthe pages 3-5).
- Subcellular localization and brain distribution: In mouse brain, KCTD16 mRNA and protein are broadly expressed with prominent enrichment across thalamic nuclei, hippocampal CA1, dentate gyrus (somata/neuropil bands), amygdala (lateral and basolateral nuclei), olfactory regions, claustrum, and septum. In the adult thalamus, GABAB receptors predominantly incorporate KCTD16 based on subtype distributions. Immunolocalization shows KCTD16 at granule cell somata and neuropil in dentate gyrus and colocalization with GABAB2 in specific layers, supporting a postsynaptic role, with additional presence in interneuron-rich layers (https://doi.org/10.1002/cne.22610) (metz2011distributionofthe pages 7-10).

3) Recent developments and latest research (prioritizing 2023–2024)
- GPCR regulation reviews: Recent Trends in Neurosciences review emphasizes constitutive binding of KCTD16 (and KCTD8/12) to GABAB2 C‑terminus as a paradigm for auxiliary control of neuromodulatory GPCRs and highlights diverse GPCR–GPCR crosstalk and effector competition (2024; https://doi.org/10.1016/j.tins.2024.05.008) (gonzalezhernandez2024emergingmodesof pages 7-9).
- KCTD–Cullin3 recognition landscape: A 2024 IJMS structural analysis using AlphaFold indicates that KCTD subcluster harboring GABAB-binding proteins (including KCTD16) shows no structural propensity for Cul3 binding via BTB, in contrast to other KCTDs that serve as Cul3 adaptors. This suggests that KCTD16’s BTB evolved primarily to assemble GBR complexes rather than Cul3 E3 ligase scaffolds (2024; https://doi.org/10.3390/ijms25031881) (balasco2024acomprehensiveanalysis pages 8-9).
- Proteomic context at synapses: A 2023 cerebellar proteomics study cataloging mGlu1 interactomes discussed KCTD family members as part of synaptic protein networks, highlighting complex, region‑specific assemblies and the possibility of indirect cross‑complex interactions in native tissue (2023; https://doi.org/10.3390/cells12091325) (mansouri2023proteinnetworksassociated pages 13-15).
- System-level physiology: A 2023 review of GABAB signaling in auditory circuits details presynaptic and postsynaptic mechanisms (GIRK, VGCC) and plasticity that are shaped by GBR auxiliary components, consistent with regional roles where KCTD16 is enriched (2023; https://doi.org/10.3389/fendo.2023.1195038) (turecek2023theroleof pages 6-7).

4) Current applications and real-world implementations
- Structural biology and mechanistic dissection: KCTD16 has enabled high-resolution determination of the GBR–auxiliary subunit interface and underpins mechanistic models for temporal control of GIRK signaling; these coordinates and models are used to guide mutational and pharmacological experiments (2019; PDB 6OCP; https://doi.org/10.1073/pnas.1903024116; 2019; https://doi.org/10.1038/s41586-019-0990-0) (zuo2019structuralbasisfor pages 1-1, zuo2019structuralbasisfor pages 9-10, zheng2019structuralbasisfor pages 2-4, zheng2019structuralbasisfor pages 12-16).
- Electrophysiology and pharmacology: Heterologous and neuronal systems employ KCTD16 co-expression to measure baclofen-evoked GIRK currents, kinetic modulation, and G protein conformational BRET assays, often comparing with KCTD8/12/12b to parse desensitization versus sustained responses (2015; https://doi.org/10.1016/j.neuropharm.2014.08.020) (rajalu2015pharmacologicalcharacterizationof pages 5-7).
- Clinical diagnostics: Incorporation of KCTD16 into GABABR cell-based assays increases sensitivity of autoantibody detection for anti-GABABR encephalitis without loss of specificity, aiding earlier diagnosis and tumor screening (2019; https://doi.org/10.1093/brain/awz094) (coevordenhameete2019theexpandedclinical pages 1-2).

5) Expert opinions and analysis from authoritative sources
- Structural consensus: Nature and PNAS structural studies converge on a bipartite mechanism: BTB/T1 mediates a 1:5 tethering of KCTD to GABAB2, while H1 pentamers engage multiple Gβγ to sculpt signal kinetics; cooperative Gβγ engagement explains rapid desensitization in KCTD12 and the more sustained modulation seen for KCTD16 lacking the canonical desensitization motif (2019; https://doi.org/10.1038/s41586-019-0990-0; https://doi.org/10.1073/pnas.1903024116) (zheng2019structuralbasisfor pages 2-4, zheng2019structuralbasisfor pages 1-2, zuo2019structuralbasisfor pages 1-3).
- Family-level specialization: 2024 IJMS analysis suggests that the GABAB‑binding KCTD clade (including KCTD16) does not structurally favor Cul3 binding, reinforcing the view that not all BTB-containing KCTDs are ubiquitin ligase adaptors; instead, KCTD16’s BTB is specialized for receptor complex assembly (2024; https://doi.org/10.3390/ijms25031881) (balasco2024acomprehensiveanalysis pages 8-9).
- Systems neuroscience perspective: 2024 Trends review frames KCTD16 as a key determinant of synaptic GPCR signaling nanoscale organization and crosstalk restraint, through constitutive receptor association and effector competition paradigms in neurons (2024; https://doi.org/10.1016/j.tins.2024.05.008) (gonzalezhernandez2024emergingmodesof pages 7-9).

6) Relevant statistics and data from recent studies
- Structural stoichiometry: 1 GABAB2 C‑terminal peptide per KCTD16 BTB/T1 pentamer (1:5), supported by crystal structure (PDB 6OCP) and mutational validation (2019; https://doi.org/10.1073/pnas.1903024116) (zuo2019structuralbasisfor pages 1-3, zuo2019structuralbasisfor pages 9-10).
- Gβγ binding/desensitization parameters (family paradigm): KCTD12 H1–Gβγ KD ~185 nM; cooperative assembly into 5:5 complexes; H1 mutants (R232D/R257D) abolish Gβγ binding and prevent desensitization (2019; https://doi.org/10.1038/s41586-019-0990-0) (zheng2019structuralbasisfor pages 2-4, zheng2019structuralbasisfor pages 12-16).
- Brain distribution: In adult mouse thalamus, KCTD16 is highly expressed across many nuclei, supporting the inference that many thalamic GBRs incorporate KCTD16; hippocampal CA1 enrichment and dentate gyrus somatic/neuropil labeling are prominent (2011; https://doi.org/10.1002/cne.22610) (metz2011distributionofthe pages 7-10).
- Clinical autoantibodies: In a cohort of 32 anti‑GABABR encephalitis patients, KCTD16 autoantibodies were present in 23/32; tumor association was 18/19 (95%) in KCTD16‑Ab+ vs 3/9 (33%) in KCTD16‑Ab− (P = 0.001). Adding KCTD16 to the GABABR cell-based assay increased sensitivity without loss of specificity (2019; https://doi.org/10.1093/brain/awz094) (coevordenhameete2019theexpandedclinical pages 1-2).

7) Subcellular site of action and role in defined signaling circuits
- Postsynaptic inhibition: By tethering to GABAB2 and shaping Gβγ availability and GIRK channel interactions, KCTD16 contributes to the amplitude and temporal profile of postsynaptic inhibitory currents, particularly in dendritic compartments where GABABRs are enriched (https://doi.org/10.1073/pnas.1903024116; https://doi.org/10.1002/cne.22610) (zuo2019structuralbasisfor pages 1-1, metz2011distributionofthe pages 7-10).
- Presynaptic modulation: Within the GBR→Gi/o framework, KCTD16-containing complexes likely modulate presynaptic Gβγ signaling to VGCCs and release probability in regions where it is abundant, consistent with physiological reviews of auditory pathways (2023; https://doi.org/10.3389/fendo.2023.1195038) (turecek2023theroleof pages 6-7).

Key evidence summary table
| Category | Key finding | Primary source (journal) | Year | URL |
|---|---|---:|---:|---|
| Identity & domains | KCTD16 is a BTB/POZ-containing KCTD family protein with an N-terminal T1/BTB oligomerization domain and C‑terminal H1 (and H2) homology regions; the T1/BTB mediates pentamer formation. (zuo2019structuralbasisfor pages 1-1, zheng2019structuralbasisfor pages 1-2) | PNAS | 2019 | https://doi.org/10.1073/pnas.1903024116 |
| Primary function | Functions as an auxiliary subunit of neuronal GABAB receptors, modulating receptor expression and the amplitude/kinetics of GIRK-mediated K+ currents. (zuo2019structuralbasisfor pages 1-1, zheng2019structuralbasisfor pages 1-2) | PNAS | 2019 | https://doi.org/10.1073/pnas.1903024116 |
| Structural mechanism — T1/BTB | The KCTD16 T1/BTB domain forms an open pentamer that binds one GABAB2 C‑terminal peptide (1:5 stoichiometry; structure deposited PDB 6OCP); interfacial residues (e.g., F80, Q34) are required for binding. (zuo2019structuralbasisfor pages 1-1, zuo2019structuralbasisfor pages 9-10) | PNAS | 2019 | https://doi.org/10.1073/pnas.1903024116 |
| Structural mechanism — H1/Gβγ | KCTD family H1 domains assemble symmetrically to engage multiple Gβγ subunits cooperatively (5:5 assemblies demonstrated for KCTD12), a mechanism proposed to strip Gβγ from GIRK and drive desensitization. (zheng2019structuralbasisfor pages 1-2, zheng2019structuralbasisfor pages 2-4) | Nature | 2019 | https://doi.org/10.1038/s41586-019-0990-0 |
| Key interaction partners | Direct/functional partners include the GABAB2 C‑terminal tail, Gβγ heterodimers, and GIRK channels; mutations at the interfaces disrupt biochemical binding and GIRK modulation. (zheng2019structuralbasisfor pages 1-2, zuo2019structuralbasisfor pages 1-1, zuo2019structuralbasisfor pages 9-10) | Nature / PNAS | 2019 | https://doi.org/10.1038/s41586-019-0990-0 |
| Signaling pathway context | Operates within the GABAB → Gi/o → Gβγ → GIRK signaling axis, thereby affecting postsynaptic inhibition and presynaptic release probability; KCTDs also modulate downstream GPCR/G-protein readouts in pharmacological assays. (zheng2019structuralbasisfor pages 1-2, rajalu2015pharmacologicalcharacterizationof pages 5-7, muntean2022membersofthe pages 3-5) | Neuropharmacology / Nature / PNAS | 2015 / 2019 / 2022 | https://doi.org/10.1016/j.neuropharm.2014.08.020 |
| Kinetic effects vs other KCTDs | KCTD12/12b contain H1 motifs that produce rapid desensitization (uncoupling Gβγ from GIRK); by contrast KCTD8 and KCTD16 typically produce primarily non‑desensitizing or sustained GABAB‑GIRK responses. (zuo2019structuralbasisfor pages 9-10, zuo2019structuralbasisfor pages 1-1) | PNAS / Neuropharmacology | 2019 / 2015 | https://doi.org/10.1073/pnas.1903024116 |
| Brain distribution / localization | In mouse brain KCTD16 shows high expression across thalamic nuclei and is enriched in hippocampal CA1, amygdala (lateral/basolateral nuclei) and dentate regions; localization can be somatic/neuropil and region‑specific. (metz2011distributionofthe pages 7-10, turecek2023theroleof pages 6-7) | Journal of Comparative Neurology | 2011 | https://doi.org/10.1002/cne.22610 |
| Clinical relevance — autoantibodies | KCTD16 autoantibodies were detected in 23/32 patients with anti‑GABABR encephalitis; KCTD16 Ab positivity strongly associated with an underlying tumour (18/19 with KCTD16 Abs vs 3/9 without; P = 0.001). (coevordenhameete2019theexpandedclinical pages 1-2) | Brain | 2019 | https://doi.org/10.1093/brain/awz094 |
| Diagnostic utility | Adding KCTD16 to GABABR cell‑based assays increased assay sensitivity for anti‑GABABR encephalitis detection without loss of specificity. (coevordenhameete2019theexpandedclinical pages 1-2) | Brain | 2019 | https://doi.org/10.1093/brain/awz094 |
| Recent developments (2023–2024) | Recent reviews/analyses (Trends, IJMS, Cells) highlight KCTD16's constitutive GABAB2 binding, roles in GPCR regulatory networks and family‑level analyses of Cullin3 partnerships that inform potential ubiquitin‑ligase adapter roles across KCTDs. (gonzalezhernandez2024emergingmodesof pages 7-9, balasco2024acomprehensiveanalysis pages 8-9, mansouri2023proteinnetworksassociated pages 13-15) | Trends in Neurosciences / Int. J. Mol. Sci. / Cells | 2024 / 2024 / 2023 | https://doi.org/10.1016/j.tins.2024.05.008 |
| Applications in research | KCTD16 has been used in high‑resolution structural studies (X‑ray/cryo‑EM), electrophysiology (baclofen‑evoked GIRK assays), proteomics and diagnostic assay development for GABAB complexes and encephalitis biomarker work. (zuo2019structuralbasisfor pages 1-1, zheng2019structuralbasisfor pages 1-2, mansouri2023proteinnetworksassociated pages 13-15) | PNAS / Nature / Cells | 2019 / 2019 / 2023 | https://doi.org/10.1073/pnas.1903024116 |

Table: Compact, cited summary of major, evidence-backed facts on human KCTD16 (UniProt Q68DU8), covering identity, structure, partners, signaling role, brain distribution, kinetics vs other KCTDs, clinical autoantibody data, and recent (2023–2024) analyses; useful as a quick reference for research and diagnostics.

Ambiguity check and scope note
- Ambiguity: The symbol “KCTD16” is used consistently in human studies and in mouse distribution studies; no conflicting gene/protein with this symbol was encountered in other organisms within the cited corpus. The functional and structural claims here are specific to Homo sapiens KCTD16 or to conserved mammalian orthologs where explicitly noted (zuo2019structuralbasisfor pages 1-1, zheng2019structuralbasisfor pages 1-2, metz2011distributionofthe pages 7-10).
- Family/function inference boundaries: While many KCTDs can act as Cul3 adaptors, 2024 modeling suggests the GABAB-binding clade (including KCTD16) does not engage Cul3 via BTB, cautioning against overgeneralization of ubiquitin E3 adaptor roles to KCTD16 (https://doi.org/10.3390/ijms25031881) (balasco2024acomprehensiveanalysis pages 8-9).

References (URLs and dates)
- Zuo et al., PNAS 2019. Structural basis for auxiliary subunit KCTD16 regulation of the GABAB receptor. Published Apr 2019. URL: https://doi.org/10.1073/pnas.1903024116 (zuo2019structuralbasisfor pages 1-1, zuo2019structuralbasisfor pages 1-3, zuo2019structuralbasisfor pages 7-7, zuo2019structuralbasisfor pages 9-10).
- Zheng et al., Nature 2019. Structural basis for KCTD-mediated rapid desensitization of GABAB signalling. Published Feb 2019. URL: https://doi.org/10.1038/s41586-019-0990-0 (zheng2019structuralbasisfor pages 2-4, zheng2019structuralbasisfor pages 12-16, zheng2019structuralbasisfor pages 1-2, zheng2019structuralbasisfor pages 18-22).
- Metz et al., J Comp Neurol 2011. Distribution of the auxiliary GABAB receptor subunits KCTD8, 12, 12b, and 16 in the mouse brain. Published Jun 2011. URL: https://doi.org/10.1002/cne.22610 (metz2011distributionofthe pages 7-10).
- Rajalu et al., Neuropharmacology 2015. Pharmacological characterization of GABAB receptor subtypes assembled with auxiliary KCTD subunits. Published Jan 2015. URL: https://doi.org/10.1016/j.neuropharm.2014.08.020 (rajalu2015pharmacologicalcharacterizationof pages 5-7).
- van Coevorden‑Hameete et al., Brain 2019. The expanded clinical spectrum of anti‑GABABR encephalitis and added value of KCTD16 autoantibodies. Advance Access Apr 22, 2019. URL: https://doi.org/10.1093/brain/awz094 (coevordenhameete2019theexpandedclinical pages 1-2).
- Tureček et al., Frontiers in Endocrinology 2023. The role of GABAB receptors in the subcortical pathways of the mammalian auditory system. Published Aug 2023. URL: https://doi.org/10.3389/fendo.2023.1195038 (turecek2023theroleof pages 6-7).
- Gonzalez‑Hernandez et al., Trends in Neurosciences 2024. Emerging modes of regulation of neuromodulatory GPCRs. Published Aug 2024. URL: https://doi.org/10.1016/j.tins.2024.05.008 (gonzalezhernandez2024emergingmodesof pages 7-9).
- Balasco et al., International Journal of Molecular Sciences 2024. A Comprehensive Analysis of the Structural Recognition between KCTD Proteins and Cullin 3. Published Feb 2024. URL: https://doi.org/10.3390/ijms25031881 (balasco2024acomprehensiveanalysis pages 8-9).
- Muntean et al., PNAS 2022. Members of the KCTD family are major regulators of cAMP signaling. Published Dec 2022. URL: https://doi.org/10.1073/pnas.2119237119 (muntean2022membersofthe pages 3-5).

Conclusion
Human KCTD16 is a BTB/POZ-domain auxiliary protein that constitutively associates with the GABAB2 C‑terminus in a 1:5 pentameric arrangement and sculpts GABAB→Gβγ→GIRK signaling kinetics. In contrast to KCTD12, KCTD16 generally supports sustained responses, consistent with differences in C‑terminal modules. Regionally enriched expression, particularly in thalamus and hippocampus, implies substantial roles in synaptic inhibition and plasticity. Clinically, KCTD16 autoantibodies are prevalent in anti‑GABABR encephalitis and improve diagnostic sensitivity, strongly flagging paraneoplastic etiologies. Recent (2023–2024) analyses refine KCTD16’s place within GPCR regulatory networks and suggest its BTB domain specializes in receptor complex assembly rather than Cul3 ligase scaffolding (zuo2019structuralbasisfor pages 1-1, zuo2019structuralbasisfor pages 1-3, zheng2019structuralbasisfor pages 2-4, metz2011distributionofthe pages 7-10, coevordenhameete2019theexpandedclinical pages 1-2, gonzalezhernandez2024emergingmodesof pages 7-9, balasco2024acomprehensiveanalysis pages 8-9).

References

1. (zuo2019structuralbasisfor pages 1-1): Hao Zuo, Ian Glaaser, Yulin Zhao, Igor Kurinov, Lidia Mosyak, Haonan Wang, Jonathan Liu, Jinseo Park, Aurel Frangaj, Emmanuel Sturchler, Ming Zhou, Patricia McDonald, Yong Geng, Paul A. Slesinger, and Qing R. Fan. Structural basis for auxiliary subunit kctd16 regulation of the gabab receptor. Proceedings of the National Academy of Sciences, 116:8370-8379, Apr 2019. URL: https://doi.org/10.1073/pnas.1903024116, doi:10.1073/pnas.1903024116. This article has 54 citations and is from a highest quality peer-reviewed journal.

2. (zheng2019structuralbasisfor pages 1-2): Sanduo Zheng, Nohely Abreu, Joshua Levitz, and Andrew C. Kruse. Structural basis for kctd-mediated rapid desensitization of gabab signalling. Nature, 567:127-131, Feb 2019. URL: https://doi.org/10.1038/s41586-019-0990-0, doi:10.1038/s41586-019-0990-0. This article has 97 citations and is from a highest quality peer-reviewed journal.

3. (zuo2019structuralbasisfor pages 7-7): Hao Zuo, Ian Glaaser, Yulin Zhao, Igor Kurinov, Lidia Mosyak, Haonan Wang, Jonathan Liu, Jinseo Park, Aurel Frangaj, Emmanuel Sturchler, Ming Zhou, Patricia McDonald, Yong Geng, Paul A. Slesinger, and Qing R. Fan. Structural basis for auxiliary subunit kctd16 regulation of the gabab receptor. Proceedings of the National Academy of Sciences, 116:8370-8379, Apr 2019. URL: https://doi.org/10.1073/pnas.1903024116, doi:10.1073/pnas.1903024116. This article has 54 citations and is from a highest quality peer-reviewed journal.

4. (zheng2019structuralbasisfor pages 2-4): Sanduo Zheng, Nohely Abreu, Joshua Levitz, and Andrew C. Kruse. Structural basis for kctd-mediated rapid desensitization of gabab signalling. Nature, 567:127-131, Feb 2019. URL: https://doi.org/10.1038/s41586-019-0990-0, doi:10.1038/s41586-019-0990-0. This article has 97 citations and is from a highest quality peer-reviewed journal.

5. (zuo2019structuralbasisfor pages 1-3): Hao Zuo, Ian Glaaser, Yulin Zhao, Igor Kurinov, Lidia Mosyak, Haonan Wang, Jonathan Liu, Jinseo Park, Aurel Frangaj, Emmanuel Sturchler, Ming Zhou, Patricia McDonald, Yong Geng, Paul A. Slesinger, and Qing R. Fan. Structural basis for auxiliary subunit kctd16 regulation of the gabab receptor. Proceedings of the National Academy of Sciences, 116:8370-8379, Apr 2019. URL: https://doi.org/10.1073/pnas.1903024116, doi:10.1073/pnas.1903024116. This article has 54 citations and is from a highest quality peer-reviewed journal.

6. (zuo2019structuralbasisfor pages 9-10): Hao Zuo, Ian Glaaser, Yulin Zhao, Igor Kurinov, Lidia Mosyak, Haonan Wang, Jonathan Liu, Jinseo Park, Aurel Frangaj, Emmanuel Sturchler, Ming Zhou, Patricia McDonald, Yong Geng, Paul A. Slesinger, and Qing R. Fan. Structural basis for auxiliary subunit kctd16 regulation of the gabab receptor. Proceedings of the National Academy of Sciences, 116:8370-8379, Apr 2019. URL: https://doi.org/10.1073/pnas.1903024116, doi:10.1073/pnas.1903024116. This article has 54 citations and is from a highest quality peer-reviewed journal.

7. (zheng2019structuralbasisfor pages 12-16): Sanduo Zheng, Nohely Abreu, Joshua Levitz, and Andrew C. Kruse. Structural basis for kctd-mediated rapid desensitization of gabab signalling. Nature, 567:127-131, Feb 2019. URL: https://doi.org/10.1038/s41586-019-0990-0, doi:10.1038/s41586-019-0990-0. This article has 97 citations and is from a highest quality peer-reviewed journal.

8. (rajalu2015pharmacologicalcharacterizationof pages 5-7): Mathieu Rajalu, Thorsten Fritzius, Lisa Adelfinger, Valerie Jacquier, Valerie Besseyrias, Martin Gassmann, and Bernhard Bettler. Pharmacological characterization of gabab receptor subtypes assembled with auxiliary kctd subunits. Neuropharmacology, 88:145-154, Jan 2015. URL: https://doi.org/10.1016/j.neuropharm.2014.08.020, doi:10.1016/j.neuropharm.2014.08.020. This article has 45 citations and is from a highest quality peer-reviewed journal.

9. (muntean2022membersofthe pages 3-5): Brian S. Muntean, Subhi Marwari, Xiaona Li, Douglas C. Sloan, Brian D. Young, James A. Wohlschlegel, and Kirill A. Martemyanov. Members of the kctd family are major regulators of camp signaling. Proceedings of the National Academy of Sciences of the United States of America, Dec 2022. URL: https://doi.org/10.1073/pnas.2119237119, doi:10.1073/pnas.2119237119. This article has 36 citations and is from a highest quality peer-reviewed journal.

10. (metz2011distributionofthe pages 7-10): Michaela Metz, Martin Gassmann, Bernd Fakler, Nicole Schaeren‐Wiemers, and Bernhard Bettler. Distribution of the auxiliary gabab receptor subunits kctd8, 12, 12b, and 16 in the mouse brain. Journal of Comparative Neurology, 519:1435-1454, Jun 2011. URL: https://doi.org/10.1002/cne.22610, doi:10.1002/cne.22610. This article has 100 citations and is from a peer-reviewed journal.

11. (gonzalezhernandez2024emergingmodesof pages 7-9): Alberto J. Gonzalez-Hernandez, Hermany Munguba, and Joshua Levitz. Emerging modes of regulation of neuromodulatory g protein-coupled receptors. Trends in Neurosciences, 47:635-650, Aug 2024. URL: https://doi.org/10.1016/j.tins.2024.05.008, doi:10.1016/j.tins.2024.05.008. This article has 23 citations and is from a highest quality peer-reviewed journal.

12. (balasco2024acomprehensiveanalysis pages 8-9): Nicole Balasco, Luciana Esposito, Giovanni Smaldone, Marco Salvatore, and Luigi Vitagliano. A comprehensive analysis of the structural recognition between kctd proteins and cullin 3. International Journal of Molecular Sciences, 25:1881, Feb 2024. URL: https://doi.org/10.3390/ijms25031881, doi:10.3390/ijms25031881. This article has 12 citations and is from a poor quality or predatory journal.

13. (mansouri2023proteinnetworksassociated pages 13-15): Mahnaz Mansouri, Leopold Kremser, Thanh-Phuong Nguyen, Yu Kasugai, Laura Caberlotto, Martin Gassmann, Bettina Sarg, Herbert Lindner, Bernhard Bettler, Lucia Carboni, and Francesco Ferraguti. Protein networks associated with native metabotropic glutamate 1 receptors (mglu1) in the mouse cerebellum. Cells, 12:1325, May 2023. URL: https://doi.org/10.3390/cells12091325, doi:10.3390/cells12091325. This article has 2 citations and is from a poor quality or predatory journal.

14. (turecek2023theroleof pages 6-7): Rostislav Tureček, Adolf Melichar, Michaela Králíková, and Bohdana Hrušková. The role of gabab receptors in the subcortical pathways of the mammalian auditory system. Frontiers in Endocrinology, Aug 2023. URL: https://doi.org/10.3389/fendo.2023.1195038, doi:10.3389/fendo.2023.1195038. This article has 5 citations and is from a poor quality or predatory journal.

15. (coevordenhameete2019theexpandedclinical pages 1-2): Marleen H van Coevorden-Hameete, Marienke A A M de Bruijn, Esther de Graaff, Danielle A E M Bastiaansen, Marco W J Schreurs, Jeroen A A Demmers, Melanie Ramberger, Esther S P Hulsenboom, Mariska M P Nagtzaam, Sanae Boukhrissi, Jan H Veldink, Jan J G M Verschuuren, Casper C Hoogenraad, Peter A E Sillevis Smitt, and Maarten J Titulaer. The expanded clinical spectrum of anti-gababr encephalitis and added value of kctd16 autoantibodies. Brain, 142:1631-1643, Apr 2019. URL: https://doi.org/10.1093/brain/awz094, doi:10.1093/brain/awz094. This article has 105 citations and is from a highest quality peer-reviewed journal.

16. (zheng2019structuralbasisfor pages 18-22): Sanduo Zheng, Nohely Abreu, Joshua Levitz, and Andrew C. Kruse. Structural basis for kctd-mediated rapid desensitization of gabab signalling. Nature, 567:127-131, Feb 2019. URL: https://doi.org/10.1038/s41586-019-0990-0, doi:10.1038/s41586-019-0990-0. This article has 97 citations and is from a highest quality peer-reviewed journal.

Citations

1. metz2011distributionofthe pages 7-10
2. gonzalezhernandez2024emergingmodesof pages 7-9
3. balasco2024acomprehensiveanalysis pages 8-9
4. mansouri2023proteinnetworksassociated pages 13-15
5. turecek2023theroleof pages 6-7
6. rajalu2015pharmacologicalcharacterizationof pages 5-7
7. coevordenhameete2019theexpandedclinical pages 1-2
8. muntean2022membersofthe pages 3-5
9. zuo2019structuralbasisfor pages 1-1
10. zheng2019structuralbasisfor pages 1-2
11. zuo2019structuralbasisfor pages 7-7
12. zheng2019structuralbasisfor pages 2-4
13. zuo2019structuralbasisfor pages 1-3
14. zuo2019structuralbasisfor pages 9-10
15. zheng2019structuralbasisfor pages 12-16
16. zheng2019structuralbasisfor pages 18-22
17. https://doi.org/10.1073/pnas.1903024116;
18. https://doi.org/10.1038/s41586-019-0990-0
19. https://doi.org/10.1073/pnas.1903024116
20. https://doi.org/10.1016/j.neuropharm.2014.08.020;
21. https://doi.org/10.1073/pnas.2119237119
22. https://doi.org/10.1002/cne.22610
23. https://doi.org/10.1016/j.tins.2024.05.008
24. https://doi.org/10.3390/ijms25031881
25. https://doi.org/10.3390/cells12091325
26. https://doi.org/10.3389/fendo.2023.1195038
27. https://doi.org/10.1016/j.neuropharm.2014.08.020
28. https://doi.org/10.1093/brain/awz094
29. https://doi.org/10.1038/s41586-019-0990-0;
30. https://doi.org/10.1073/pnas.1903024116,
31. https://doi.org/10.1038/s41586-019-0990-0,
32. https://doi.org/10.1016/j.neuropharm.2014.08.020,
33. https://doi.org/10.1073/pnas.2119237119,
34. https://doi.org/10.1002/cne.22610,
35. https://doi.org/10.1016/j.tins.2024.05.008,
36. https://doi.org/10.3390/ijms25031881,
37. https://doi.org/10.3390/cells12091325,
38. https://doi.org/10.3389/fendo.2023.1195038,
39. https://doi.org/10.1093/brain/awz094,

Introduction and Key Concepts

KCTD16 (Potassium Channel Tetramerization Domain-containing protein 16) is a human gene (UniProt Q68DU8) encoding a BTB/POZ domain protein in the KCTD family. Despite the name, KCTD proteins are not ion channels; they are soluble adaptor or scaffold proteins defined by an N-terminal BTB domain (pmc.ncbi.nlm.nih.gov). KCTD16 is one of four KCTD subunits (along with KCTD8, KCTD12, and KCTD12b) that serve as auxiliary subunits of the GABA_B (γ-aminobutyric acid type B) receptor in the brain (pmc.ncbi.nlm.nih.gov). The GABA_B receptor is a metabotropic G-protein-coupled receptor (GPCR) that mediates slow inhibitory neurotransmission. It consists of principal subunits (GABA_B1 and GABA_B2) forming the core receptor, and auxiliary subunits like KCTD16 which modulate the receptor’s signaling output (pmc.ncbi.nlm.nih.gov). KCTD16’s association with GABA_B receptors is supported by proteomic studies that identified KCTD8/12/16 as stable components of native GABA_B receptor complexes (pmc.ncbi.nlm.nih.gov). In essence, KCTD16 acts as a non-catalytic regulatory protein that fine-tunes GABA_B receptor function, rather than directly performing enzyme or transporter activity. This modulatory role is significant because GABA_B receptor malfunction is linked to neurological and mood disorders (spasticity, epilepsy, addiction, anxiety) (pmc.ncbi.nlm.nih.gov). Understanding KCTD16 is therefore key to understanding how inhibitory synaptic signals are shaped and how their dysregulation might contribute to disease.

Gene and Protein Features: The human KCTD16 gene (also known as KIAA1317) is predominantly expressed in the brain (showing biased brain enrichment in RNA profiling) (www.ncbi.nlm.nih.gov). Its protein product is ~285 amino acids and contains a BTB/POZ domain (also called a T1 domain) at the N-terminus, which mediates protein oligomerization. KCTD16 belongs to the “clade F” subgroup of KCTDs, along with KCTD8 and KCTD12, which share sequence homology in their C-termini (pmc.ncbi.nlm.nih.gov). Notably, unlike many BTB-domain proteins that function as Cullin-3 ubiquitin ligase adaptors, KCTD16 does not bind to the Cul3 scaffold and is not known to participate in ubiquitin E3 ligase complexes (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). Instead, its BTB domain primarily mediates assembly into a higher-order complex. Biophysical studies have revealed that the BTB domain of KCTD16 forms an oligomeric structure (a pentamer) with a distinctive “open” pentameric conformation (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). Within GABA_B receptor complexes, KCTD16 and related subunits can attach as homo-pentamers or even form hetero-oligomers (mixing different KCTD types), wrapping around the cytosolic tail of the GABA_B2 subunit (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). This unique pentameric assembly is a hallmark of the KCTD family’s interaction with receptors and contrasts with the dimeric assemblies of BTB domains in typical Cullin3-adaptor proteins.

Structure and Domain Organization

BTB/POZ Domain: The N-terminal BTB domain (∼130 amino acids) of KCTD16 is responsible for both KCTD16’s self-oligomerization and its docking to the GABA_B2 receptor. A high-resolution crystal structure (2019) of the human KCTD16 BTB domain bound to a GABA_B2 tail peptide (residues 895–909) revealed how five KCTD16 subunits form a pentameric ring encircling the receptor’s cytoplasmic tail (pmc.ncbi.nlm.nih.gov). Point mutations in this interface (e.g. KCTD16 Phe80→Ala in the BTB domain) abolish binding to GABA_B2, confirming that the BTB domain is the contact site for the receptor (pmc.ncbi.nlm.nih.gov). The BTB domain also underlies the ability of different KCTDs to form mixed complexes. Studies have shown KCTD16 can form hetero-pentamers with KCTD12 or KCTD8 when co-expressed, producing intermediate functional properties (pmc.ncbi.nlm.nih.gov). This suggests the BTB domains of clade F KCTDs are compatible enough to co-assemble, diversifying the potential regulatory outcomes at GABA_B receptors. Notably, the KCTD16 BTB domain adopts an “open” pentamer conformation (a somewhat expanded pentamer) as opposed to the more symmetric closed pentamers seen in some other KCTDs (pmc.ncbi.nlm.nih.gov). This open architecture may relate to its inability to bind Cul3 (pmc.ncbi.nlm.nih.gov) and possibly to how it accommodates the receptor tail. Indeed, a comparative structural analysis in 2017 found that KCTD16 (and the related KCTD1) form unusual pentamers and do not interact with Cul3, whereas other KCTDs form tighter oligomers that readily bind Cul3 (pmc.ncbi.nlm.nih.gov).

C-terminal Domains (H1 and H2): Beyond the BTB domain, KCTD16 contains two conserved C-terminal regions, historically termed the H1 and H2 domains (homology domains 1 and 2) (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). These domains are crucial for KCTD16’s regulatory function. The H1 domain (present in KCTD8, 12, and 16) mediates interactions with G-protein beta-gamma subunits (Gβγ) and is directly responsible for altering GABA_B signaling kinetics (pmc.ncbi.nlm.nih.gov). In contrast, the H2 domain exists in KCTD8 and KCTD16 but is absent in KCTD12, and it serves an autoinhibitory role: the H2 region of KCTD16 can fold back onto its H1 domain to modulate or restrain its activity (pmc.ncbi.nlm.nih.gov). Functional assays demonstrated that the H1 domain of KCTD12 alone is sufficient to induce rapid desensitization of GABA_B responses, whereas KCTD16’s H2 domain counteracts such an effect in KCTD16 (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). In other words, KCTD16’s H2 segment prevents the H1 segment from over-sequestering the G-protein, thereby suppressing rapid desensitization that would otherwise occur. A 2012 biochemical study provided evidence for this: swapping or mutating these domains showed that only KCTD8 and KCTD16 (which have H2) generated sustained, non-desensitizing currents, whereas KCTD12 (lacking H2) caused pronounced desensitization (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). This domain organization (BTB–H1–H2) defines KCTD16’s function as a modulator that can both accelerate and limit receptor signaling, as discussed below.

Role in GABA_B Receptor Function

Auxiliary Subunit Function: KCTD16 is an integral auxiliary component of the GABA_B receptor signaling complex. GABA_B receptors are obligatory heterodimers (GABA_B1 binds the neurotransmitter GABA, and GABA_B2 couples to G-proteins) that signal via Gi/Go proteins to regulate downstream effectors like ion channels (pmc.ncbi.nlm.nih.gov). When KCTD16 associates with the GABA_B2 subunit’s intracellular tail, it does not affect GABA binding directly, but it profoundly influences the receptor’s signaling kinetics and pharmacology (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). Specifically, KCTD16 (as well as KCTD8 and KCTD12) determines how quickly and for how long the GABA_B receptor can activate G-protein gated inward-rectifier K^+ channels (GIRKs) and inhibit Ca^2+ channels on neurons. Experimental studies comparing receptor responses have shown that:

• Faster Onset: The presence of KCTD subunits speeds up the onset of GABA_B-mediated currents. All three auxiliary subunits (8, 12, 16) were found to increase the activation rate of GIRK currents following GABA_B stimulation, compared to receptors without KCTDs (pmc.ncbi.nlm.nih.gov). This is attributed to a “pre-assembled” signaling complex: KCTD16 tethers parts of the G-protein in close proximity to the receptor and effector channel, so that when GABA binds, the channel opens more rapidly. A recent study (Biochem. Pharmacol. 2024) confirmed that KCTD proteins can preassemble specific Gβγ subunits with the GABA_B receptor, markedly accelerating GIRK channel gating upon receptor activation (pmc.ncbi.nlm.nih.gov). In practical terms, neurons expressing KCTD16 exhibit a quicker inhibitory postsynaptic potential in response to GABA, enhancing the timing precision of synaptic inhibition.

• Desensitization and Persistence: While KCTD12 causes the GABA_B response to desensitize rapidly (fade away even in continued presence of agonist), KCTD16 has the opposite effect – it largely prevents rapid desensitization, allowing a more sustained response (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). Electrophysiological studies in heterologous cells have demonstrated this stark difference. In cells expressing GABA_B plus KCTD12, GABA-triggered K^+ currents peak and then quickly diminish (due to KCTD12 uncoupling the G-protein), whereas with KCTD16, the induced currents remain near peak as long as GABA is present (pmc.ncbi.nlm.nih.gov). KCTD16’s H2 domain is responsible for this sustained signaling – it blocks the desensitizing action that the H1 domain would otherwise exert (pmc.ncbi.nlm.nih.gov). Therefore, KCTD16-containing GABA_B receptors produce more persistent inhibitory signals. This has been observed in vitro and is supported by chimeric domain-swap experiments: inserting the H2 domain of KCTD16 into KCTD12 can convert KCTD12 into a non-desensitizing variant (pmc.ncbi.nlm.nih.gov). In summary, KCTD16 acts as a brake on desensitization, promoting longer-lasting GABA_B receptor activity.

• Pharmacological Modulation: By altering kinetics, KCTD16 also subtly changes the pharmacological profile of GABA_B receptors. For example, receptors with different KCTD subunits can show different sensitivities to agonists or differences in how quickly they shut off after agonist removal (pmc.ncbi.nlm.nih.gov). A 2017 study found that hetero-oligomers of KCTD12/16 confer unique kinetic and pharmacological properties not seen with either subunit alone (pmc.ncbi.nlm.nih.gov). KCTD16 might also influence the efficacy of allosteric modulators or the extent of GABA_B’s effect on second messengers (like cAMP), although this is an area of ongoing research. It’s worth noting that GABA_B receptors are clinical drug targets (e.g. baclofen is a GABA_B agonist for spasticity), and thus understanding KCTD16’s effect has therapeutic implications. If KCTD16 makes receptor signaling more sustained, drugs that enhance KCTD16 expression or function could potentially prolong GABA_B signaling in disorders where it is beneficial (conversely, dampening KCTD12’s effect might prevent excessive desensitization in chronic treatment settings) (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov).

Mechanistic Basis – G-protein Interaction: KCTD16 modulates receptor signaling by directly interacting with the G-protein subunits released upon receptor activation. Normally, when GABA_B is stimulated, the Gα_o/i subunit inhibits adenylate cyclase and the Gβγ dimer opens GIRK channels and inhibits Ca^2+ channels. KCTD16, tethered to GABA_B2, interacts with the Gβγ dimer via its H1 domain (pmc.ncbi.nlm.nih.gov). Biochemical and biophysical experiments have shown that KCTD16 can bind Gβγ even before receptor activation, effectively sequestering Gβγ near the receptor at rest (pmc.ncbi.nlm.nih.gov). In a 2023 study using bioluminescence resonance energy transfer (BRET), KCTD16 exhibited a high basal association with Gβγ and only a modest further change after receptor stimulation, indicating that KCTD16-Gβγ complexes exist prior to agonist binding (pmc.ncbi.nlm.nih.gov). This pre-association explains the accelerated channel activation: the Gβγ is already “in position” to gate the K^+ channel once GABA triggers Gα subunit dissociation. However, unlike KCTD12, KCTD16’s grip on Gβγ is self-limited by the H2 domain. Structural insights highlight this difference: a 2019 cryo-EM structure of KCTD12’s H1 domain bound to Gβ_1γ_2 showed a pentameric H1 “tentacle” surrounded by five Gβγ dimers (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). KCTD12 effectively cages multiple Gβγ subunits, pulling them away from the membrane which causes rapid channel closure (desensitization) (pmc.ncbi.nlm.nih.gov). KCTD16’s H2 domain likely prevents such a tight Gβγ binding configuration, so Gβγ remains available to continue signaling. In line with this model, in vitro assays demonstrated that mutating KCTD16’s H2 domain leads to enhanced desensitization, behaving more like KCTD12 (pmc.ncbi.nlm.nih.gov). Figurely, one can imagine the KCTD16 pentamer dangling from the receptor tail: upon GABA binding, KCTD16 helps push the Gα subunit off (facilitating Gβγ activation of GIRK), but then refrains from clamping onto Gβγ, allowing the channel to stay open (pmc.ncbi.nlm.nih.gov). This model – where KCTD12 is an “off-switch” and KCTD16 a “sustain-switch” for GABA_B signaling – is supported by multiple lines of evidence including co-immunoprecipitation (showing KCTD16 robustly pulls down Gβγ in cell extracts) (pmc.ncbi.nlm.nih.gov) and electrophysiology in neurons (pmc.ncbi.nlm.nih.gov).

Biological Processes and Localization

Cellular and Tissue Localization: KCTD16 is primarily a neuronal protein. It is expressed throughout the central nervous system, with mRNA and protein found in many brain regions (Human Protein Atlas data indicate highest expression in brain, with very low levels in peripheral tissues) (www.ncbi.nlm.nih.gov). Within neurons, KCTD16 is localized to the cytoplasmic side of the plasma membrane wherever GABA_B receptors reside. GABA_B receptors are present both post-synaptically (on dendrites of neurons, mediating slow inhibitory postsynaptic currents) and pre-synaptically (on nerve terminals, modulating neurotransmitter release) (pmc.ncbi.nlm.nih.gov). Auxillary subunits like KCTD16 have been identified in both contexts. For instance, one study noted that KCTD16 (and KCTD8/12) are present in excitatory as well as inhibitory neurons, indicating a broad role in tuning synaptic transmission across different circuit types (pmc.ncbi.nlm.nih.gov). KCTD16 lacks any transmembrane region; it is peripherally attached to membranes via protein–protein interactions. Specifically, KCTD16 co-assembles with GABA_B2 subunits in the endoplasmic reticulum and Golgi during receptor trafficking, and this complex trafficks to the cell surface as a unit (pmc.ncbi.nlm.nih.gov). Evidence for this comes from co-expression experiments where KCTD subunits were required for efficient surface expression of GABA_B in certain neurons (pmc.ncbi.nlm.nih.gov) (pubmed.ncbi.nlm.nih.gov). Moreover, imaging of tagged KCTD16 has shown a punctate distribution in neurites consistent with clustering at GABA_B receptor sites (e.g. in dendritic spines or axon terminals where GABA_B receptors concentrate).

Functionally, KCTD16 operates at the interface of the receptor and intracellular signaling pathways, making it part of the inhibitory signaling microdomain. By shaping GABA_B receptor signaling, KCTD16 indirectly influences downstream processes such as neuronal excitability, synaptic plasticity, and network oscillations. For example, a GABA_B receptor on a presynaptic terminal can inhibit neurotransmitter release via Gβγ-mediated inhibition of voltage-gated Ca^2+ channels. If that receptor complex contains KCTD16, the inhibition might set in quickly and last longer during a burst of GABA, compared to another synapse with KCTD12 where inhibition would fade more quickly. Similarly, postsynaptically, KCTD16-containing receptors mediate longer GIRK channel openings, affecting the duration of slow inhibitory postsynaptic potentials. These differences can translate into measurable effects on behavior and physiology, as described below.

Biological Processes and Pathways: KCTD16 is chiefly involved in the GABAergic inhibitory pathway. It plays a role in:
- Regulation of postsynaptic membrane potential: By controlling GIRK channel activity through GABA_B, KCTD16 helps regulate the postsynaptic excitability of neurons (www.ncbi.nlm.nih.gov). In GO annotations, KCTD16 has been linked to GPCR signaling involved in postsynaptic membrane potential regulation, which reflects its modulatory effect on ion channel coupling.
- Regulation of presynaptic transmitter release: Via presynaptic GABA_B receptors, KCTD16 can influence neurotransmitter release (GABA_B activation on axon terminals inhibits Ca^2+ influx and transmitter release). KCTD16’s presence may prolong this inhibition, thus affecting synaptic transmission dynamics during repetitive activity (www.ncbi.nlm.nih.gov). A recent study in 2021 found that auxiliary KCTD subunits modulate GABA_B-receptor-mediated suppression of neurotransmitter release from specific neurons (e.g. habenula terminals) (pmc.ncbi.nlm.nih.gov). Although that study focused on KCTD8/12, it underscores the pathway KCTD16 participates in: GABA_B to Gβγ to Ca^2+ channel inhibition in terminals.
- Second messenger regulation: Through Gα_o, GABA_B receptors inhibit adenylate cyclase and reduce cAMP levels. KCTD16 may indirectly modulate this Gα-mediated pathway. Interestingly, a 2023 analysis reported that many KCTDs, possibly including KCTD16, can dampen Gβγ-dependent sensitization of adenylyl cyclase (a feedback phenomenon) (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). In striatal neurons, overexpression of certain KCTDs blunted the increase in cAMP that normally follows prolonged Gi signaling, presumably by sequestering Gβγ. While that study highlighted KCTD2/5/17, the shared capacity of KCTD16 to bind Gβγ suggests it might have a similar influence on cAMP regulation under specific conditions. This places KCTD16 in the context of broader GPCR signaling beyond just ion channel regulation.

Overall, KCTD16’s activity is tightly connected to the GABA_B-G protein-GIRK/Ca^2+ channel signaling axis. By controlling the timing and duration of this inhibitory signaling, KCTD16 contributes to processes like fear memory, mood regulation, and seizure susceptibility. Indeed, GABA_B receptors are known to modulate network excitability and synaptic plasticity, and KCTD16 fine-tunes these effects, as evidenced by phenotypes in mice (next section) and associations with psychiatric conditions.

Experimental Insights and Phenotypes

Knockout Mouse Phenotypes: Genetic studies provide insight into KCTD16’s function in vivo. Kctd16 knockout mice have been generated and analyzed for behavioral and physiological changes. Notably, mice lacking KCTD16 exhibit altered fear memory processing (pmc.ncbi.nlm.nih.gov). In one study, Kctd16^-/- mice demonstrated abnormalities in fear learning paradigms (e.g. auditory cued fear conditioning) compared to wild-type mice (pubmed.ncbi.nlm.nih.gov). While the detailed results showed some differences distinct from Kctd12^-/- mice, both knockouts point to KCTD subunits affecting emotional memory circuits. Specifically, Kctd16 knockout mice displayed changes in fear extinction and recall, suggesting that prolonged inhibitory signaling via GABA_B (which would normally be supported by KCTD16) is important for normal fear memory consolidation and extinction (pmc.ncbi.nlm.nih.gov). These behavioral “endophenotypes” link KCTD16 to the neural circuitry of the amygdala and hippocampus, where fear memories are encoded. Supporting this, in vitro electrophysiology in hippocampal slices from Kctd16^-/- mice showed modified GABA_B-receptor-mediated currents, consistent with the loss of the sustained component normally conferred by KCTD16 (the currents in knockouts desensitized more quickly) (pubmed.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov).

This phenotype parallels findings in Kctd12 knockout mice, which have increased anxiety-like behavior and enhanced cued fear learning (pubmed.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). The fact that removing either KCTD16 or KCTD12 impacts fear and anxiety behaviors underscores the importance of properly timed GABA_B inhibition in regulating emotion. It has been proposed that KCTD16 might be more relevant in certain brain regions or developmental periods – for instance, KCTD16 mRNA is enriched in the forebrain (cortex, hippocampus) during development, hinting it could shape the maturation of synaptic inhibition and plasticity. More research is needed, but the available evidence firmly places KCTD16 in the context of neuropsychiatric-relevant phenotypes. As one expert review noted, disruption of KCTD8/12/16 could contribute to “related conditions” given GABA_B’s implication in disorders like epilepsy, depression, and schizophrenia (pmc.ncbi.nlm.nih.gov). No gross developmental abnormalities were reported in Kctd16 knockout mice, suggesting KCTD16’s role is more in neural communication than in brain morphogenesis.

Disease Associations: While no single-gene Mendelian disorders are linked to KCTD16, there are hints from human genetics and clinical studies that KCTD16 may be involved in neuropsychiatric conditions. The KCTD16 gene lies on chromosome 5q31.3; this region has not been as prominently highlighted in genome-wide association studies as the 16p11.2 locus containing KCTD13, for example. However, because KCTD16 modulates GABA_B receptors – and GABA_B dysfunction has been associated with mood disorders, addiction, and epilepsy – researchers have posited that KCTD16 variants could influence disease risk. A 2019 review pointed out that elevated KCTD12 protein levels were observed in brains of patients with depression and schizophrenia, linking GABA_B receptor modulators to those illnesses (pmc.ncbi.nlm.nih.gov). By analogy, changes in KCTD16 expression or function might also affect mood regulation. Indeed, both KCTD12 and KCTD16 are mentioned as potentially contributing to neuropsychiatric phenotypes (with KCTD12 more firmly tied via human data, and KCTD16 via animal data) (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). So far, direct genetic associations for KCTD16 are limited, but one study did find that KCTD16 was among genes with altered expression in stress-related mouse models (though changes in KCTD16 have not been confirmed in human patient tissues).

On a different front, autoimmune neurological disease has unexpectedly highlighted KCTD16’s clinical relevance. In 2019, an examination of patients with anti-GABA_B receptor encephalitis (a rare autoimmune disorder causing seizures and limbic encephalitis) discovered that many patients also had antibodies against KCTD16 (academic.oup.com). Specifically, KCTD16 autoantibodies were detected in 23 of 32 (72%) patients with anti-GABA_BR encephalitis, whereas none of 329 control subjects had such antibodies (academic.oup.com). The presence of anti-KCTD16 antibodies correlated strongly with a paraneoplastic origin of the encephalitis: 95% of patients with KCTD16 antibodies had an underlying tumor (often small-cell lung carcinoma, SCLC), compared to 33% of those without KCTD16 antibodies (academic.oup.com). In other words, KCTD16 has become recognized as a marker of cancer-associated GABA_B autoimmunity. This finding makes sense because certain tumors (like SCLC) aberrantly express neuronal proteins such as GABA_B receptors and KCTD16, triggering an immune response. Clinically, this is important – including KCTD16 in diagnostic cell-based assays for GABA_B receptor antibodies improved the sensitivity of detecting this encephalitis, without loss of specificity (academic.oup.com). Moreover, patients with KCTD16 antibodies tended to have more severe disease (higher antibody titers in cerebrospinal fluid and more frequent seizures/status epilepticus) (academic.oup.com) (academic.oup.com). Thus, KCTD16 is now implicated in a real-world medical context: it is a target of autoantibodies causing neurological illness, and it hints at the need to survey for cancer when such antibodies are found. This discovery underscores that KCTD16 is not only functionally important for neurons but also sufficiently antigenic and unique to serve as an immune target.

Beyond the nervous system, KCTD16 has not been widely linked to other organ systems. However, some large-scale studies have started to evaluate KCTD gene family expression in cancers. In a 2025 analysis of ovarian cancer, members of the KCTD family were found to have dysregulated expression, including KCTD16 being significantly upregulated in ovarian tumor tissues relative to normal tissues (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). The same study reported that high KCTD16 expression was associated with worse patient prognosis (for instance, patients with elevated KCTD16 had a hazard ratio ~1.28 for poorer survival, p = 0.029) (pmc.ncbi.nlm.nih.gov). While KCTD16’s role in tumors is not understood (it may be incidental or related to altered cell signaling in cancer cells), such data suggest KCTD16 could be explored as part of a panel of biomarkers. Interestingly, other KCTDs (e.g. KCTD11, an established Cul3 adaptor) have tumor suppressor functions. KCTD16 lacks the Cul3 interaction, so if it influences cancer cell behavior, it might be through modulating GPCR signaling or other protein interactions in the cell. These emerging findings open new questions about whether KCTD16 has unrecognized roles beyond the brain, but neurological function remains its primary context.

Recent Developments (2023–2024) and Expert Perspectives

Research on KCTD16 and its family has accelerated in recent years, with contemporary studies providing deeper mechanistic insight and exploring clinical applications:

• Comprehensive KCTD–G Protein Interactions: In 2023, Sloan et al. (J. Biol. Chem., March 2023) systematically screened all 25 human KCTD family members for their ability to interact with G-protein βγ subunits. They found that nearly all KCTDs can bind Gβγ, suggesting a conserved property of the family (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). KCTD16 was confirmed to bind Gβγ, although it showed an interesting behavior of high constitutive binding (high basal BRET signal) with only a mild change upon receptor activation (pmc.ncbi.nlm.nih.gov). This aligns with earlier notions that KCTD16 preassembles with Gβγ at rest. The study also noted that different KCTDs varied in their efficacy of dampening Gβγ-driven signaling; some (like KCTD2/5/17) strongly blunted Gβγ effects on cAMP production (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). KCTD16 was not highlighted as a major modulator of cAMP in that assay, possibly because in a heterologous system its impact is more specific to the GABA_B context. Nonetheless, the broad takeaway is that KCTD16 is part of a family-wide mechanism of GPCR signal modulation via Gβγ sequestration, expanding our understanding of how widespread this regulatory mode might be. Experts have pointed out that KCTD proteins represent a novel class of GPCR modulators, “well positioned to shape GPCR pharmacology” due to their ability to interface with G proteins (pmc.ncbi.nlm.nih.gov). This has spurred interest in targeting KCTD–Gβγ interactions as a way to fine-tune GPCR signals in disease contexts.

• Structural Mechanisms of Desensitization: Building on structures of KCTD16 and KCTD12, researchers have proposed refined models for how these subunits act as molecular timers for receptor signaling. A 2017 Nature study (Fritzius et al., 2017) described KCTD12 as an “off-switch” that induces rapid desensitization by capturing Gβγ (pmc.ncbi.nlm.nih.gov). In contrast, KCTD16 (and KCTD8) were described as having an “auto-inhibited state” that prevents them from immediately binding Gβγ, thus delaying or preventing desensitization (pmc.ncbi.nlm.nih.gov). The 2019 PNAS study by Zuo et al. provided the first crystal structure of a KCTD16 oligomer with a GABA_B2 fragment, solidifying the concept that the receptor’s tail threads into the center of a KCTD pentamer (pmc.ncbi.nlm.nih.gov). Qing Fan, one of the senior authors, highlighted that this structure “sheds light on the assembly of the GABA_B receptor signaling complex” and reveals a clear binding interface that could be targeted to disrupt or enhance KCTD16-receptor interaction (pmc.ncbi.nlm.nih.gov). Knowing this interface at atomic detail opens the door for drug design – for instance, small molecules that stabilize KCTD16 on the receptor might prolong GABA_B signaling, which could be useful in certain neurological disorders. Conversely, molecules that block KCTD12 binding might prevent excessive desensitization and enhance GABA_B responses in conditions like depression (where GABA_B function may be deficient). Such therapeutic speculation is in early stages, but it stems directly from these structural and mechanistic insights.

• Autoantibody Diagnostics: As discussed, the recognition of KCTD16 as an autoantigen in GABA_B receptor encephalitis (first reported in Brain, June 2019) is now shaping clinical practice. Neurologists now test for anti-KCTD16 antibodies in patients with unexplained seizures and encephalitic presentations. The 2019 study by de Bruijn et al. demonstrated that adding KCTD16 to cell-based antibody assays increased detection sensitivity from about 59% (with only GABA_B1/B2 in the assay) to ~84% when KCTD16 was included (academic.oup.com). Since most of these KCTD16-positive cases are paraneoplastic, this lab finding directly guides oncological investigations (e.g. screening for a hidden small-cell lung cancer in a patient with limbic encephalitis) (academic.oup.com) (academic.oup.com). It’s a prime example of a basic science discovery (KCTD16’s role in the receptor) translating into a real-world diagnostic tool within a short time. Furthermore, it provides a biological rationale for the severe seizures observed in these patients: antibodies might be disrupting KCTD16 function, thereby altering GABA_B receptor kinetics and making neuronal inhibition less sustained, potentially promoting hyperexcitability.

• Cancer Genomics: While KCTD16 is not a well-known oncogene or tumor suppressor, the 2025 Cancer Medicine study (Zhang et al., 2025) exemplifies a growing research trend of surveying “hidden” gene families in cancer. This study found KCTD16 mRNA was up-regulated in ovarian cancer cell lines and tumors, alongside KCTD5, KCTD9, and KCTD12, whereas some other KCTDs were down-regulated (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). The authors performed ROC analysis and found KCTD16 had a moderate diagnostic value (AUC ~0.8) for distinguishing ovarian cancer tissue from normal (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). Although KCTD16’s function in ovarian cancer is unclear, one hypothesis is that changes in GPCR signaling pathways in tumors (many ovarian cancers have aberrant GPCR and G-protein activity) might select for altered expression of GPCR modulators like KCTDs. Additionally, KCTD16 has a CpG island in its promoter, and the 2025 study noted that DNA methylation changes in several KCTD genes correlated inversely with their expression in cancer (pmc.ncbi.nlm.nih.gov). For KCTD16 specifically, hypomethylation might explain its over-expression in tumors. Importantly, this research is still early and primarily descriptive. Experts caution that high expression of KCTD16 could either be a passenger effect or potentially influence cell signaling to confer growth advantages. Regardless, such findings expand the relevance of KCTD16 beyond the brain, suggesting it may be involved in cellular pathways that, when dysregulated, contribute to diseases like cancer.

Expert Commentary: Scientific interest in KCTD16 mirrors the broader interest in KCTD proteins as modulators of key signaling pathways. A 2019 review by Teng et al. in CNS Neuroscience & Therapeutics argued that the “poorly characterized human KCTD gene family” deserves deeper investigation due to emerging evidence linking various KCTDs to neurological disorders (pmc.ncbi.nlm.nih.gov). The authors highlighted KCTD12’s ties to bipolar disorder and KCTD13’s involvement in neurodevelopmental disorders, while noting that KCTD16, KCTD8, and KCTD12 form a functionally related subgroup influencing neurotransmitter receptor signaling (pmc.ncbi.nlm.nih.gov). They described recent structural studies (citing work on KCTD12 and KCTD16) as providing “mechanisms of regulating membrane channel activities through modulation of distinct GTPases” (pmc.ncbi.nlm.nih.gov) – essentially pointing out that KCTDs regulate ion channels by interfacing with G-proteins (a novel mechanism for protein regulation). In the same review, the model of KCTD12/16 action on GIRK channels is summarized, emphasizing how KCTD12’s sequestration of Gβγ accelerates channel deactivation, whereas KCTD16’s H2 domain prevents this sequestration (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). The review underscores that while KCTD12 has been more extensively studied (due to psychiatric genetic links), KCTD16 likely plays complementary roles and could be implicated in “related conditions” especially where GABA_B signaling is a factor (pmc.ncbi.nlm.nih.gov).

Another expert perspective can be found in a 2022 commentary on G protein-gated K^+ channels (Luo et al., 2022, Am J Physiol Cell Physiol). The authors note that the discovery of KCTD auxiliary subunits has “significantly expanded our understanding of GABA_B receptor function,” allowing the receptor’s inhibitory signals to be “tuned by cell-specific expression of KCTD8, 12, or 16” (since different neurons express different ratios of these subunits) (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). They further mention that targeting these subunits could yield new pharmacological avenues – for instance, a molecule that enhances KCTD16’s interaction with GABA_B2 might prolong GABA_B-mediated inhibition therapeutically. While such drugs are hypothetical at present, the concept reflects a growing recognition of auxiliary proteins like KCTD16 as drug targets themselves or as part of receptor complexes to target.

In summary, current expert consensus portrays KCTD16 as a critical modulatory subunit that defines the timing of inhibitory GABA_B signals. It is part of a mechanism nature uses to diversify GPCR signaling outcomes, and its dysfunction or removal can have notable neural consequences. The most recent research (2023–2024) has reinforced KCTD16’s role in Gβγ management and highlighted its relevance in contexts ranging from autoimmune encephalitis diagnostics to cancer biomarker studies. As one paper succinctly stated, KCTD subunits like 16 “induce desensitization of K^+ currents in response to GABA_B activation in a subtype-specific manner” (academic.oup.com) – a reminder that each KCTD subtype (8, 12, 16) confers unique properties. Going forward, investigating KCTD16 in specific neuron types and disease models (e.g. stress, epilepsy, or mood disorder models) will be important to fully elucidate its functions. With structural biology providing detailed interaction maps, and clinical findings giving real-world significance, KCTD16 has moved from an obscure KIAA gene to a protein of substantial interest in neuroscience and beyond.

References: (Publication dates and sources are included in citation brackets)

Citations

1. AnnotationURLCitation(end_index=515, start_index=333, title='A Comprehensive Analysis of the Structural Recognition between KCTD Proteins and Cullin 3 - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10856315/#:~:text=domains%20embedded%20in%20potassium%20channels,little%20involvement%20in%20potassium%20channeling')
2. AnnotationURLCitation(end_index=865, start_index=691, title='KCTD: A new gene family involved in neurodevelopmental and neuropsychiatric disorders - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC6566181/#:~:text=Mouse%20Kctd8%2C%20Kctd12%2C%20Kctd12b%20,Therefore%2C%20disruption%20of%20the%20auxiliary')
3. AnnotationURLCitation(end_index=1327, start_index=1153, title='Structural basis for auxiliary subunit KCTD16 regulation of the GABAB receptor - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC6486783/#:~:text=Malfunction%20of%20the%20receptor%20is,to%20neurotransmitters%2C%20while%20the%20auxiliary')
4. AnnotationURLCitation(end_index=1655, start_index=1491, title='GABAB receptor auxiliary subunits modulate Cav2.3-mediated release from medial habenula terminals - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC8121548/#:~:text=Four%20KCTD%20subunits%2C%20KCTD8%2C%2012%2C,subunits%20are%20composed%20of%20an')
5. AnnotationURLCitation(end_index=2159, start_index=1985, title='Structural basis for auxiliary subunit KCTD16 regulation of the GABAB receptor - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC6486783/#:~:text=Malfunction%20of%20the%20receptor%20is,to%20neurotransmitters%2C%20while%20the%20auxiliary')
6. AnnotationURLCitation(end_index=2681, start_index=2490, title='KCTD16 potassium channel tetramerization domain containing 16 [Homo sapiens (human)] - Gene - NCBI', type='url_citation', url='https://www.ncbi.nlm.nih.gov/gene?Cmd=DetailsSearch&Db=gene&Term=57528#:~:text=Expression%20Biased%20expression%20in%20brain,other%20tissues%20See%20more%20Orthologs')
7. AnnotationURLCitation(end_index=3097, start_index=2967, title='KCTD: A new gene family involved in neurodevelopmental and neuropsychiatric disorders - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC6566181/#:~:text=3,in%20neurotransmitter%20receptor%20signaling')
8. AnnotationURLCitation(end_index=3497, start_index=3304, title='Structural complexity in the KCTD family of Cullin3-dependent E3 ubiquitin ligases - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC5664961/#:~:text=domains%20with%20the%20exception%20of,KCTD13%20%28K_%7Bd%7D%E2%80%89%3D%E2%80%89100%E2%80%85nM%29%2C%20KCTD10')
9. AnnotationURLCitation(end_index=3665, start_index=3498, title='Structural complexity in the KCTD family of Cullin3-dependent E3 ubiquitin ligases - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC5664961/#:~:text=Evolutionarily%20distant%20from%20these%20family,here%20that%20this%20geometry%20is')
10. AnnotationURLCitation(end_index=4027, start_index=3909, title='Structural complexity in the KCTD family of Cullin3-dependent E3 ubiquitin ligases - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC5664961/#:~:text=,Cul3%20and%20were%20observed%20to')
11. AnnotationURLCitation(end_index=4221, start_index=4028, title='Structural complexity in the KCTD family of Cullin3-dependent E3 ubiquitin ligases - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC5664961/#:~:text=domains%20with%20the%20exception%20of,KCTD13%20%28K_%7Bd%7D%E2%80%89%3D%E2%80%89100%E2%80%85nM%29%2C%20KCTD10')
12. AnnotationURLCitation(end_index=4597, start_index=4433, title='GABAB receptor auxiliary subunits modulate Cav2.3-mediated release from medial habenula terminals - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC8121548/#:~:text=Four%20KCTD%20subunits%2C%20KCTD8%2C%2012%2C,subunits%20are%20composed%20of%20an')
13. AnnotationURLCitation(end_index=4724, start_index=4598, title='KCTD: A new gene family involved in neurodevelopmental and neuropsychiatric disorders - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC6566181/#:~:text=increase%20the%20activation%20rate%20of,19')
14. AnnotationURLCitation(end_index=5474, start_index=5348, title='KCTD: A new gene family involved in neurodevelopmental and neuropsychiatric disorders - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC6566181/#:~:text=increase%20the%20activation%20rate%20of,19')
15. AnnotationURLCitation(end_index=5774, start_index=5648, title='KCTD: A new gene family involved in neurodevelopmental and neuropsychiatric disorders - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC6566181/#:~:text=increase%20the%20activation%20rate%20of,19')
16. AnnotationURLCitation(end_index=6163, start_index=5999, title='GABAB receptor auxiliary subunits modulate Cav2.3-mediated release from medial habenula terminals - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC8121548/#:~:text=Four%20KCTD%20subunits%2C%20KCTD8%2C%2012%2C,subunits%20are%20composed%20of%20an')
17. AnnotationURLCitation(end_index=6612, start_index=6494, title='Structural complexity in the KCTD family of Cullin3-dependent E3 ubiquitin ligases - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC5664961/#:~:text=,Cul3%20and%20were%20observed%20to')
18. AnnotationURLCitation(end_index=6871, start_index=6678, title='Structural complexity in the KCTD family of Cullin3-dependent E3 ubiquitin ligases - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC5664961/#:~:text=domains%20with%20the%20exception%20of,KCTD13%20%28K_%7Bd%7D%E2%80%89%3D%E2%80%89100%E2%80%85nM%29%2C%20KCTD10')
19. AnnotationURLCitation(end_index=7306, start_index=7139, title='Structural complexity in the KCTD family of Cullin3-dependent E3 ubiquitin ligases - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC5664961/#:~:text=Evolutionarily%20distant%20from%20these%20family,here%20that%20this%20geometry%20is')
20. AnnotationURLCitation(end_index=7619, start_index=7487, title='Structural basis for auxiliary subunit KCTD16 regulation of the GABAB receptor - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC6486783/#:~:text=of%20KCTD12%20and%20KCTD12b%20mediate,20%2C%2023')
21. AnnotationURLCitation(end_index=7786, start_index=7620, title='KCTD: A new gene family involved in neurodevelopmental and neuropsychiatric disorders - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC6566181/#:~:text=H2%20is%20not%20present%20in,from%20the%20inhibited%20trimeric%20G%E2%80%90protein')
22. AnnotationURLCitation(end_index=8189, start_index=8023, title='KCTD: A new gene family involved in neurodevelopmental and neuropsychiatric disorders - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC6566181/#:~:text=H2%20is%20not%20present%20in,from%20the%20inhibited%20trimeric%20G%E2%80%90protein')
23. AnnotationURLCitation(end_index=8572, start_index=8406, title='KCTD: A new gene family involved in neurodevelopmental and neuropsychiatric disorders - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC6566181/#:~:text=H2%20is%20not%20present%20in,from%20the%20inhibited%20trimeric%20G%E2%80%90protein')
24. AnnotationURLCitation(end_index=8937, start_index=8771, title='KCTD: A new gene family involved in neurodevelopmental and neuropsychiatric disorders - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC6566181/#:~:text=H2%20is%20not%20present%20in,from%20the%20inhibited%20trimeric%20G%E2%80%90protein')
25. AnnotationURLCitation(end_index=9070, start_index=8938, title='Structural basis for auxiliary subunit KCTD16 regulation of the GABAB receptor - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC6486783/#:~:text=of%20KCTD12%20and%20KCTD12b%20mediate,20%2C%2023')
26. AnnotationURLCitation(end_index=9610, start_index=9497, title='Structural basis for auxiliary subunit KCTD16 regulation of the GABAB receptor - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC6486783/#:~:text=%2820%2C%2022%29,In%20genetic')
27. AnnotationURLCitation(end_index=9743, start_index=9611, title='Structural basis for auxiliary subunit KCTD16 regulation of the GABAB receptor - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC6486783/#:~:text=of%20KCTD12%20and%20KCTD12b%20mediate,20%2C%2023')
28. AnnotationURLCitation(end_index=10430, start_index=10270, title='KCTD: A new gene family involved in neurodevelopmental and neuropsychiatric disorders - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC6566181/#:~:text=further%20advance%20the%20field%20overall,B2%7D%20%28amino%20acid%20residues')
29. AnnotationURLCitation(end_index=10792, start_index=10628, title='GABAB receptor auxiliary subunits modulate Cav2.3-mediated release from medial habenula terminals - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC8121548/#:~:text=Four%20KCTD%20subunits%2C%20KCTD8%2C%2012%2C,subunits%20are%20composed%20of%20an')
30. AnnotationURLCitation(end_index=10934, start_index=10793, title='KCTD: A new gene family involved in neurodevelopmental and neuropsychiatric disorders - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC6566181/#:~:text=synaptic%20transmission%20by%20indirectly%20regulating,33')
31. AnnotationURLCitation(end_index=11633, start_index=11492, title='KCTD: A new gene family involved in neurodevelopmental and neuropsychiatric disorders - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC6566181/#:~:text=synaptic%20transmission%20by%20indirectly%20regulating,33')
32. AnnotationURLCitation(end_index=12217, start_index=12048, title='KCTD: A new gene family involved in neurodevelopmental and neuropsychiatric disorders - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC6566181/#:~:text=channels%20through%20trimeric%20G%E2%80%90proteins,B2%7D%20%28amino%20acid%20residues')
33. AnnotationURLCitation(end_index=12779, start_index=12666, title='Structural basis for auxiliary subunit KCTD16 regulation of the GABAB receptor - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC6486783/#:~:text=%2820%2C%2022%29,In%20genetic')
34. AnnotationURLCitation(end_index=12888, start_index=12780, title='KCTD: A new gene family involved in neurodevelopmental and neuropsychiatric disorders - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC6566181/#:~:text=GABA_,channel%29.%20Then')
35. AnnotationURLCitation(end_index=13322, start_index=13209, title='Structural basis for auxiliary subunit KCTD16 regulation of the GABAB receptor - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC6486783/#:~:text=%2820%2C%2022%29,In%20genetic')
36. AnnotationURLCitation(end_index=13631, start_index=13465, title='KCTD: A new gene family involved in neurodevelopmental and neuropsychiatric disorders - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC6566181/#:~:text=H2%20is%20not%20present%20in,from%20the%20inhibited%20trimeric%20G%E2%80%90protein')
37. AnnotationURLCitation(end_index=14024, start_index=13911, title='Structural basis for auxiliary subunit KCTD16 regulation of the GABAB receptor - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC6486783/#:~:text=%2820%2C%2022%29,In%20genetic')
38. AnnotationURLCitation(end_index=14596, start_index=14432, title='GABAB receptor auxiliary subunits modulate Cav2.3-mediated release from medial habenula terminals - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC8121548/#:~:text=Four%20KCTD%20subunits%2C%20KCTD8%2C%2012%2C,subunits%20are%20composed%20of%20an')
39. AnnotationURLCitation(end_index=14904, start_index=14740, title='GABAB receptor auxiliary subunits modulate Cav2.3-mediated release from medial habenula terminals - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC8121548/#:~:text=Four%20KCTD%20subunits%2C%20KCTD8%2C%2012%2C,subunits%20are%20composed%20of%20an')
40. AnnotationURLCitation(end_index=15685, start_index=15561, title='Structural basis for auxiliary subunit KCTD16 regulation of the GABAB receptor - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC6486783/#:~:text=studies%2C%20the%20KCTD12%20gene%20has,B')
41. AnnotationURLCitation(end_index=15859, start_index=15686, title='KCTD: A new gene family involved in neurodevelopmental and neuropsychiatric disorders - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC6566181/#:~:text=inhibitory%20and%20excitatory%20neurons,mice%20exhibit%20related%20phenotypes%20including')
42. AnnotationURLCitation(end_index=16421, start_index=16258, title='Multiple potassium channel tetramerization domain (KCTD) family members interact with Gβγ, with effects on cAMP signaling - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC9976452/#:~:text=H1%20domain%20that%20is%20exclusive,was%20sufficient%20for%20interaction%20with')
43. AnnotationURLCitation(end_index=16736, start_index=16593, title='Multiple potassium channel tetramerization domain (KCTD) family members interact with Gβγ, with effects on cAMP signaling - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC9976452/#:~:text=KCTD5%2C%20and%20KCTD12%29,In%20addition%2C%20we%20revealed')
44. AnnotationURLCitation(end_index=17133, start_index=16990, title='Multiple potassium channel tetramerization domain (KCTD) family members interact with Gβγ, with effects on cAMP signaling - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC9976452/#:~:text=KCTD5%2C%20and%20KCTD12%29,In%20addition%2C%20we%20revealed')
45. AnnotationURLCitation(end_index=17691, start_index=17560, title='KCTD: A new gene family involved in neurodevelopmental and neuropsychiatric disorders - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC6566181/#:~:text=GABA_,together%2C%20the%20proposed%20model%20is')
46. AnnotationURLCitation(end_index=17800, start_index=17692, title='KCTD: A new gene family involved in neurodevelopmental and neuropsychiatric disorders - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC6566181/#:~:text=GABA_,channel%29.%20Then')
47. AnnotationURLCitation(end_index=18087, start_index=17939, title='KCTD: A new gene family involved in neurodevelopmental and neuropsychiatric disorders - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC6566181/#:~:text=KCTD12%20H1%20bound%20to%20G%CE%B2_,19%20A%20role%20for%20KCTD12')
48. AnnotationURLCitation(end_index=18528, start_index=18362, title='KCTD: A new gene family involved in neurodevelopmental and neuropsychiatric disorders - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC6566181/#:~:text=H2%20is%20not%20present%20in,from%20the%20inhibited%20trimeric%20G%E2%80%90protein')
49. AnnotationURLCitation(end_index=18928, start_index=18780, title='KCTD: A new gene family involved in neurodevelopmental and neuropsychiatric disorders - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC6566181/#:~:text=KCTD12%20H1%20bound%20to%20G%CE%B2_,19%20A%20role%20for%20KCTD12')
50. AnnotationURLCitation(end_index=19309, start_index=19162, title='Multiple potassium channel tetramerization domain (KCTD) family members interact with Gβγ, with effects on cAMP signaling - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC9976452/#:~:text=match%20at%20L165%20Given%20that,myc%20tag%20to%20the%20carboxy')
51. AnnotationURLCitation(end_index=19456, start_index=19343, title='Structural basis for auxiliary subunit KCTD16 regulation of the GABAB receptor - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC6486783/#:~:text=%2820%2C%2022%29,In%20genetic')
52. AnnotationURLCitation(end_index=19983, start_index=19792, title='KCTD16 potassium channel tetramerization domain containing 16 [Homo sapiens (human)] - Gene - NCBI', type='url_citation', url='https://www.ncbi.nlm.nih.gov/gene?Cmd=DetailsSearch&Db=gene&Term=57528#:~:text=Expression%20Biased%20expression%20in%20brain,other%20tissues%20See%20more%20Orthologs')
53. AnnotationURLCitation(end_index=20475, start_index=20312, title='KCTD: A new gene family involved in neurodevelopmental and neuropsychiatric disorders - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC6566181/#:~:text=considered%20auxiliary%20subunits%20of%20the,to%20contribute%20to%20bipolar%20I')
54. AnnotationURLCitation(end_index=20915, start_index=20752, title='KCTD: A new gene family involved in neurodevelopmental and neuropsychiatric disorders - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC6566181/#:~:text=considered%20auxiliary%20subunits%20of%20the,to%20contribute%20to%20bipolar%20I')
55. AnnotationURLCitation(end_index=21376, start_index=21212, title='GABAB receptor auxiliary subunits modulate Cav2.3-mediated release from medial habenula terminals - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC8121548/#:~:text=Four%20KCTD%20subunits%2C%20KCTD8%2C%2012%2C,subunits%20are%20composed%20of%20an')
56. AnnotationURLCitation(end_index=21678, start_index=21529, title='KCTD8 and KCTD12 Facilitate Axonal Expression of GABAB Receptors in Habenula Cholinergic Neurons - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC8896537/#:~:text=KCTD8%20and%20KCTD12%20Facilitate%20Axonal,5%7D%2C%20Minmin%20Luo')
57. AnnotationURLCitation(end_index=21816, start_index=21679, title='Behavioural endophenotypes in mice lacking the auxiliary GABAB receptor subunit KCTD16 - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/27717812/#:~:text=subunit%20KCTD16%20,pathophysiology%20of%20a%20number%20of')
58. AnnotationURLCitation(end_index=23467, start_index=23279, title='KCTD16 potassium channel tetramerization domain containing 16 [Homo sapiens (human)] - Gene - NCBI', type='url_citation', url='https://www.ncbi.nlm.nih.gov/gene?Cmd=DetailsSearch&Db=gene&Term=57528#:~:text=Summary%20Predicted%20to%20enable%20G,involved%20in%20regulation%20of%20presynaptic')
59. AnnotationURLCitation(end_index=24173, start_index=23985, title='KCTD16 potassium channel tetramerization domain containing 16 [Homo sapiens (human)] - Gene - NCBI', type='url_citation', url='https://www.ncbi.nlm.nih.gov/gene?Cmd=DetailsSearch&Db=gene&Term=57528#:~:text=Summary%20Predicted%20to%20enable%20G,involved%20in%20regulation%20of%20presynaptic')
60. AnnotationURLCitation(end_index=24519, start_index=24355, title='GABAB receptor auxiliary subunits modulate Cav2.3-mediated release from medial habenula terminals - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC8121548/#:~:text=Four%20KCTD%20subunits%2C%20KCTD8%2C%2012%2C,subunits%20are%20composed%20of%20an')
61. AnnotationURLCitation(end_index=25186, start_index=25013, title='Multiple potassium channel tetramerization domain (KCTD) family members interact with Gβγ, with effects on cAMP signaling - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC9976452/#:~:text=examining%20sensitization%20of%20the%20adenylyl,to%20shape%20GPCR%20signal%20transmission')
62. AnnotationURLCitation(end_index=25347, start_index=25187, title='Multiple potassium channel tetramerization domain (KCTD) family members interact with Gβγ, with effects on cAMP signaling - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC9976452/#:~:text=D2R%E2%86%92G%CE%B1i%20signaling,Curiously%2C%20KCTD9%20slightly%20inhibited')
63. AnnotationURLCitation(end_index=26714, start_index=26590, title='Structural basis for auxiliary subunit KCTD16 regulation of the GABAB receptor - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC6486783/#:~:text=studies%2C%20the%20KCTD12%20gene%20has,B')
64. AnnotationURLCitation(end_index=26957, start_index=26866, title='Behavioural endophenotypes in mice lacking the auxiliary GABAB receptor subunit KCTD16 - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/27717812/#:~:text=,mice%20show')
65. AnnotationURLCitation(end_index=27497, start_index=27373, title='Structural basis for auxiliary subunit KCTD16 regulation of the GABAB receptor - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC6486783/#:~:text=studies%2C%20the%20KCTD12%20gene%20has,B')
66. AnnotationURLCitation(end_index=28038, start_index=27910, title='Behavioural endophenotypes in mice lacking the auxiliary GABAB receptor subunit KCTD16 - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/27717812/#:~:text=determine%20the%20kinetics%20of%20the,mice%20show')
67. AnnotationURLCitation(end_index=28152, start_index=28039, title='Structural basis for auxiliary subunit KCTD16 regulation of the GABAB receptor - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC6486783/#:~:text=%2820%2C%2022%29,In%20genetic')
68. AnnotationURLCitation(end_index=28383, start_index=28292, title='Behavioural endophenotypes in mice lacking the auxiliary GABAB receptor subunit KCTD16 - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/27717812/#:~:text=,mice%20show')
69. AnnotationURLCitation(end_index=28520, start_index=28384, title='KCTD: A new gene family involved in neurodevelopmental and neuropsychiatric disorders - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC6566181/#:~:text=disorders,several%20cancers%20not%20discussed%20here')
70. AnnotationURLCitation(end_index=29458, start_index=29285, title='KCTD: A new gene family involved in neurodevelopmental and neuropsychiatric disorders - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC6566181/#:~:text=inhibitory%20and%20excitatory%20neurons,mice%20exhibit%20related%20phenotypes%20including')
71. AnnotationURLCitation(end_index=30583, start_index=30430, title='KCTD: A new gene family involved in neurodevelopmental and neuropsychiatric disorders - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC6566181/#:~:text=subunits%20KCTD8%2C%20KCTD12%2C%20and%20KCTD16,64%20Consistent%20with')
72. AnnotationURLCitation(end_index=30985, start_index=30855, title='KCTD: A new gene family involved in neurodevelopmental and neuropsychiatric disorders - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC6566181/#:~:text=3,in%20neurotransmitter%20receptor%20signaling')
73. AnnotationURLCitation(end_index=31138, start_index=30986, title='KCTD: A new gene family involved in neurodevelopmental and neuropsychiatric disorders - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC6566181/#:~:text=KCTD12%20and%20KCTD16,function%20and%2For%20GTPase%20modulated%20ion')
74. AnnotationURLCitation(end_index=31864, start_index=31715, title='expanded clinical spectrum of anti-GABABR encephalitis and added value of KCTD16 autoantibodies | Brain | Oxford Academic', type='url_citation', url='https://academic.oup.com/brain/article/142/6/1631/5476117#:~:text=and%20cell,that%20were%20screened%20sufficiently%2C%2018%2F19')
75. AnnotationURLCitation(end_index=32183, start_index=32034, title='expanded clinical spectrum of anti-GABABR encephalitis and added value of KCTD16 autoantibodies | Brain | Oxford Academic', type='url_citation', url='https://academic.oup.com/brain/article/142/6/1631/5476117#:~:text=and%20cell,that%20were%20screened%20sufficiently%2C%2018%2F19')
76. AnnotationURLCitation(end_index=32586, start_index=32453, title='expanded clinical spectrum of anti-GABABR encephalitis and added value of KCTD16 autoantibodies | Brain | Oxford Academic', type='url_citation', url='https://academic.oup.com/brain/article/142/6/1631/5476117#:~:text=match%20at%20L243%20%2895,Thirteen%20patients')
77. AnnotationURLCitation(end_index=33219, start_index=33049, title='expanded clinical spectrum of anti-GABABR encephalitis and added value of KCTD16 autoantibodies | Brain | Oxford Academic', type='url_citation', url='https://academic.oup.com/brain/article/142/6/1631/5476117#:~:text=addition%20of%20KCTD16%20to%20the,with%20prominent%2C%20severe%20seizures%2C%20but')
78. AnnotationURLCitation(end_index=33505, start_index=33392, title='expanded clinical spectrum of anti-GABABR encephalitis and added value of KCTD16 autoantibodies | Brain | Oxford Academic', type='url_citation', url='https://academic.oup.com/brain/article/142/6/1631/5476117#:~:text=%2895,Thirteen%20patients')
79. AnnotationURLCitation(end_index=33687, start_index=33506, title='expanded clinical spectrum of anti-GABABR encephalitis and added value of KCTD16 autoantibodies | Brain | Oxford Academic', type='url_citation', url='https://academic.oup.com/brain/article/142/6/1631/5476117#:~:text=encephalitis%20patients%20with%20KCTD16%20antibodies,without%20KCTD16%20antibodies%20had%20an')
80. AnnotationURLCitation(end_index=34624, start_index=34454, title='Mechanistic Insights Into the Tumor‐Driving and Diagnostic Roles of KCTD Family Genes in Ovarian Cancer: An Integrated In Silico and In\xa0Vitro Analysis - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC12365668/#:~:text=KCTD5%2C%20KCTD12%2C%20and%20KCTD16%20were,genes%2C%20except%20for%20KCTD9%2C%20which')
81. AnnotationURLCitation(end_index=34792, start_index=34625, title='Mechanistic Insights Into the Tumor‐Driving and Diagnostic Roles of KCTD Family Genes in Ovarian Cancer: An Integrated In Silico and In\xa0Vitro Analysis - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC12365668/#:~:text=match%20at%20L457%20results%20in,in%20tissue%20samples%2C%20indicating%20potential')
82. AnnotationURLCitation(end_index=35126, start_index=34996, title='Mechanistic Insights Into the Tumor‐Driving and Diagnostic Roles of KCTD Family Genes in Ovarian Cancer: An Integrated In Silico and In\xa0Vitro Analysis - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC12365668/#:~:text=match%20at%20L544%20KCTD10%2C%20KCTD12%2C,029')
83. AnnotationURLCitation(end_index=36472, start_index=36300, title='Multiple potassium channel tetramerization domain (KCTD) family members interact with Gβγ, with effects on cAMP signaling - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC9976452/#:~:text=G%20protein%E2%80%93coupled%20receptors%20,a%20live%20cell%20bioluminescence%20resonance')
84. AnnotationURLCitation(end_index=36636, start_index=36473, title='Multiple potassium channel tetramerization domain (KCTD) family members interact with Gβγ, with effects on cAMP signaling - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC9976452/#:~:text=H1%20domain%20that%20is%20exclusive,was%20sufficient%20for%20interaction%20with')
85. AnnotationURLCitation(end_index=36961, start_index=36818, title='Multiple potassium channel tetramerization domain (KCTD) family members interact with Gβγ, with effects on cAMP signaling - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC9976452/#:~:text=KCTD5%2C%20and%20KCTD12%29,In%20addition%2C%20we%20revealed')
86. AnnotationURLCitation(end_index=37375, start_index=37212, title='Multiple potassium channel tetramerization domain (KCTD) family members interact with Gβγ, with effects on cAMP signaling - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC9976452/#:~:text=downstream%20through%20the%20cAMP%20pathway,G%CE%B2%CE%B3%20has%20yet%20to%20be')
87. AnnotationURLCitation(end_index=37536, start_index=37376, title='Multiple potassium channel tetramerization domain (KCTD) family members interact with Gβγ, with effects on cAMP signaling - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC9976452/#:~:text=D2R%E2%86%92G%CE%B1i%20signaling,Curiously%2C%20KCTD9%20slightly%20inhibited')
88. AnnotationURLCitation(end_index=38189, start_index=38097, title='Multiple potassium channel tetramerization domain (KCTD) family members interact with Gβγ, with effects on cAMP signaling - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC9976452/#:~:text=Abstract')
89. AnnotationURLCitation(end_index=38800, start_index=38652, title='KCTD: A new gene family involved in neurodevelopmental and neuropsychiatric disorders - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC6566181/#:~:text=KCTD12%20H1%20bound%20to%20G%CE%B2_,19%20A%20role%20for%20KCTD12')
90. AnnotationURLCitation(end_index=39144, start_index=38978, title='KCTD: A new gene family involved in neurodevelopmental and neuropsychiatric disorders - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC6566181/#:~:text=H2%20is%20not%20present%20in,from%20the%20inhibited%20trimeric%20G%E2%80%90protein')
91. AnnotationURLCitation(end_index=39487, start_index=39361, title='KCTD: A new gene family involved in neurodevelopmental and neuropsychiatric disorders - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC6566181/#:~:text=increase%20the%20activation%20rate%20of,19')
92. AnnotationURLCitation(end_index=39861, start_index=39742, title='Structural basis for auxiliary subunit KCTD16 regulation of the GABAB receptor - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC6486783/#:~:text=Human%20GABA_,B%7D%20receptor%20and')
93. AnnotationURLCitation(end_index=41101, start_index=40931, title='expanded clinical spectrum of anti-GABABR encephalitis and added value of KCTD16 autoantibodies | Brain | Oxford Academic', type='url_citation', url='https://academic.oup.com/brain/article/142/6/1631/5476117#:~:text=addition%20of%20KCTD16%20to%20the,with%20prominent%2C%20severe%20seizures%2C%20but')
94. AnnotationURLCitation(end_index=41429, start_index=41316, title='expanded clinical spectrum of anti-GABABR encephalitis and added value of KCTD16 autoantibodies | Brain | Oxford Academic', type='url_citation', url='https://academic.oup.com/brain/article/142/6/1631/5476117#:~:text=%2895,Thirteen%20patients')
95. AnnotationURLCitation(end_index=41575, start_index=41430, title='expanded clinical spectrum of anti-GABABR encephalitis and added value of KCTD16 autoantibodies | Brain | Oxford Academic', type='url_citation', url='https://academic.oup.com/brain/article/142/6/1631/5476117#:~:text=of%20KCTD16%20antibodies%20points%20towards,based%20assay')
96. AnnotationURLCitation(end_index=42555, start_index=42403, title='Mechanistic Insights Into the Tumor‐Driving and Diagnostic Roles of KCTD Family Genes in Ovarian Cancer: An Integrated In Silico and In\xa0Vitro Analysis - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC12365668/#:~:text=the%20expression%20levels%20of%20KCTD,for%20each%20KCTD%20gene%20to')
97. AnnotationURLCitation(end_index=42726, start_index=42556, title='Mechanistic Insights Into the Tumor‐Driving and Diagnostic Roles of KCTD Family Genes in Ovarian Cancer: An Integrated In Silico and In\xa0Vitro Analysis - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC12365668/#:~:text=KCTD5%2C%20KCTD12%2C%20and%20KCTD16%20were,genes%2C%20except%20for%20KCTD9%2C%20which')
98. AnnotationURLCitation(end_index=43016, start_index=42876, title='Mechanistic Insights Into the Tumor‐Driving and Diagnostic Roles of KCTD Family Genes in Ovarian Cancer: An Integrated In Silico and In\xa0Vitro Analysis - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC12365668/#:~:text=match%20at%20L403%20%28Figure%C2%A01B%29,Figure%C2%A01B')
99. AnnotationURLCitation(end_index=43137, start_index=43017, title='Mechanistic Insights Into the Tumor‐Driving and Diagnostic Roles of KCTD Family Genes in Ovarian Cancer: An Integrated In Silico and In\xa0Vitro Analysis - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC12365668/#:~:text=%28Figure%C2%A01B%29,Figure%C2%A01B')
100. AnnotationURLCitation(end_index=43758, start_index=43582, title='Mechanistic Insights Into the Tumor‐Driving and Diagnostic Roles of KCTD Family Genes in Ovarian Cancer: An Integrated In Silico and In\xa0Vitro Analysis - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC12365668/#:~:text=KCTD12%2C%20KCTD10%2C%20and%20KCTD16%20show,the%20expression%20and%20promoter%20methylation')
101. AnnotationURLCitation(end_index=44773, start_index=44627, title='KCTD: A new gene family involved in neurodevelopmental and neuropsychiatric disorders - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC6566181/#:~:text=focusing%20efforts%20to%20dissect%20their,KCTD11%29%20and%20an')
102. AnnotationURLCitation(end_index=45150, start_index=45020, title='KCTD: A new gene family involved in neurodevelopmental and neuropsychiatric disorders - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC6566181/#:~:text=3,in%20neurotransmitter%20receptor%20signaling')
103. AnnotationURLCitation(end_index=45504, start_index=45337, title='KCTD: A new gene family involved in neurodevelopmental and neuropsychiatric disorders - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC6566181/#:~:text=and%20structure%E2%80%90based%20studies%20,functions%20may%20be%20disease%20related')
104. AnnotationURLCitation(end_index=46026, start_index=45857, title='KCTD: A new gene family involved in neurodevelopmental and neuropsychiatric disorders - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC6566181/#:~:text=channels%20through%20trimeric%20G%E2%80%90proteins,B2%7D%20%28amino%20acid%20residues')
105. AnnotationURLCitation(end_index=46158, start_index=46027, title='KCTD: A new gene family involved in neurodevelopmental and neuropsychiatric disorders - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC6566181/#:~:text=GABA_,together%2C%20the%20proposed%20model%20is')
106. AnnotationURLCitation(end_index=46560, start_index=46407, title='KCTD: A new gene family involved in neurodevelopmental and neuropsychiatric disorders - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC6566181/#:~:text=subunits%20KCTD8%2C%20KCTD12%2C%20and%20KCTD16,64%20Consistent%20with')
107. AnnotationURLCitation(end_index=47189, start_index=47025, title='GABAB receptor auxiliary subunits modulate Cav2.3-mediated release from medial habenula terminals - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC8121548/#:~:text=Four%20KCTD%20subunits%2C%20KCTD8%2C%2012%2C,subunits%20are%20composed%20of%20an')
108. AnnotationURLCitation(end_index=47363, start_index=47190, title='KCTD: A new gene family involved in neurodevelopmental and neuropsychiatric disorders - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC6566181/#:~:text=inhibitory%20and%20excitatory%20neurons,mice%20exhibit%20related%20phenotypes%20including')
109. AnnotationURLCitation(end_index=48612, start_index=48447, title='expanded clinical spectrum of anti-GABABR encephalitis and added value of KCTD16 autoantibodies | Brain | Oxford Academic', type='url_citation', url='https://academic.oup.com/brain/article/142/6/1631/5476117#:~:text=KCTD%20family%20members%20show%20distinct,specific%20manner%20%28Schwenk%20et')